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ABSTRACT 
DISCOVERY AND CHARACTERIZATION OF NOVEL SUBSTRATE SELECTIVE 
INHIBITORS OF HUMAN MRP1 (ABCC1) 
ANGELINA SAMPSON 
2019 
Multidrug resistance protein 1 (MRP1/ABCC1) actively transports a variety of drugs, toxic 
molecules and important physiological substrates across the plasma membrane. It can 
confer broad-spectrum drug resistance and can decrease the bioavailability of many 
important drugs such as anti-cancer agents, antibiotics, antivirals, antidepressants and anti-
inflammatory drugs. Calcein-AM, a fluorescent reporter commonly used for studying 
compound interactions with MRP1 was recently used in the development of a high content 
imaging-based assay by our group. This assay was robust and had better sensitivity than 
fluorescent plate readouts.  The assay identified 12 MRP1 inhibitors after screening an anti-
cancer library of 386 compounds. Due to the multiple distinct substrate binding sites of 
MRP1, we sought to use different fluorescent probes to identify substrate selective 
inhibitors which were likely missed by the calcein-AM screening. The high content 
imaging-based uptake assay was modified using doxorubicin (anticancer drug) and CRO-
9 (dye) as fluorescent reporters which vary in structure and function. The doxorubicin 
assay, after screening the same 386 compound library identified a total of 28 MRP1 
inhibitors including 16 inhibitors that have not been previously reported as inhibitors of 
MRP1. The CRO-9 assay identified a total of 50 MRP1 inhibitors including 19 additional 
inhibitors that have never been reported as inhibitors of MRP1. These 50 MRP1 inhibitors 
xvi 
 
included 10 out of 12 hits identified using calcein-AM and 27 out of 28 inhibitors 
discovered through the doxorubicin assay. MRP1 inhibition was confirmed using flow 
cytometry, confocal microscopy and membrane-based transport assays. Selected drugs 
were evaluated for their ability to reverse resistance of MRP1-overexpressing H69AR lung 
cancer cells against various substrates. From the doxorubicin screening, mifepristone and 
doramapimod were the most effective in reversing MRP1 mediated resistance whiles 
celecoxib exhibited selective MRP1 inhibition. From the hits identified through the CRO-
9-based screening, LY2603618 and ZSTK474 were the most effective in reversing MRP1 
mediated resistance in H69AR cells. Together, our findings signify the effectiveness and 
value of doxorubicin and CRO-9 based high content screening approach. Anti-cancer 
agents that exhibit MRP1 inhibition may be used to reverse multidrug resistance or to 
improve the efficacy and reduce the toxicity of various cancer chemotherapies.
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1.0 Scope of the Study 
The significance of this study is to identify novel inhibitors of the multidrug resistance 
protein 1 (MRP1) from a unique anticancer library using a high throughput imaging-based 
assay with different fluorescent reporters. This chapter explores literature on ATP Binding 
Cassette (ABC) transporters, their structure and function, and their role in the development 
of multidrug resistance in cancer. The chapter also covers modulators of ABC transporters 
and how they can be used for different therapeutic purposes. The literature regarding some 
of the common traditional methods used for screening for modulators of key ABC 
transporters such as P-gp, MRP1 and BCRP is carefully examined. The chapter then 
highlights the literature regarding high content imaging-based assay using fluorescence 
reporters, the main technique for the identification of MRP1 inhibitors. The chapter finally 
concludes by looking at the rationale of the current study and importance of profiling drug 
interaction with ABC transporters. It also addresses potential utilization of our findings in 
overcoming multidrug resistance.  
 
1.1 Introduction to ABC transporters 
ABC transporters represent a large evolutionarily conserved superfamily of membrane 
proteins ubiquitous in practically all living organisms. In the human genome, a total of 48 
ABC transporter genes have been identified and are classified into seven subfamilies, 
designated A to G (Figure 1.1) according to sequence homology and structural organization 
[1]. 
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Figure 1.1 Classification of ABC transporter family genes identified in the human genome 
 
 
Most ABC transporters can shuttle endogenous molecules and xenobiotics across 
membranes. ABC transporters play a role in physiological functions such as tissue defense 
against exogenous molecules and maintenance of balance between antioxidant and free 
radical concentrations (the MRPs), detoxification (P-gp), absorptive and secretory 
activities (ABCBs and MRPs), antigen presentations (ABCB2 and ABCB3) and lipid 
metabolism (ABCA1 and ABCGs) [2]. ABC transporters also play a role in the transport 
of various physiological substrates such as amino acids, peptides, lipids, and inorganic 
3 
 
ions. The importance of ABC transporters is highlighted by the fact that mutations in 
various ABC transporter genes are associated with human diseases. These diseases include 
cystic fibrosis (ABCC7), Dubin-Johnson syndrome (ABCC2), gout (ABCG2), intrahepatic 
cholestasis (ABCB4), schizophrenia (ABCA13), sitosterolemia (ABCG5 and ABCG8), 
Tangier disease (ABCA1), surfactant metabolism syndrome (ABCA3), Harlequin-type 
ichthyosis (ABCA12), inflammatory bowel disease (ABCB1), and adrenoleukodystrophy 
(ABCD1) [2,3]. Nine ABC transporters are associated with drug resistance due to their 
ability to efflux xenobiotics with majority from the ABCC subfamily These are P-
glycoprotein (P-gp/ABCB1), Multidrug resistance proteins (MRP1-MRP7), and breast 
cancer resistance protein (BCRP/ABCG2) [5]. Accumulating evidence has indicated a key 
role of these transporters in governing the transit of both endogenous and drugs substrates 
and their metabolites across major organs and physiological barriers (Figure 1. 2) such as 
liver, kidney, blood-brain barrier, blood-testis barrier, and non-polarized cells [5, 6]. The 
cystic fibrosis transmembrane conductance regulator (CFTR/ABCC7) and sulfonyl urea 
receptor (SUR, ABCC8) are ATP-dependent protein channels but do not directly transport 
drugs [8]. ABC transporters that efflux drugs such as P-gp, MRP1 and BCRP are known 
to affect drug efficacy and toxicity [8, 9]. Thus, it is essential to assess their interactions 
with new drugs in the drug discovery and development process.  
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 Figure 1.2 Localization of ABC transporters at four pharmacological barriers 
Top: blood-brain barrier; mid-left: hepatocyte; mid-right: proximal tubule cell; enterocyte) 
[10, 11, 12]. Arrows indicate the direction of transport. Common name of transporters is 
shown. 
 
1.2 Structure and function of ABC transporters 
ABC transporters efflux specific substrates across cell membranes against a concentration 
gradient using energy derived from ATP binding and hydrolysis. The general structure of 
ABC transporters comprises of nucleotide binding domains (NBD) located on the 
cytoplasmic side of the membrane and two sets of membrane spanning domains (MSD). 
The NBDs of all ABC transporters have 3 conserved motifs; Walker A, B and C. Walker 
A and Walker B motifs are essential for ATP- binding and hydrolysis reactions [14]. The 
Walker A motif binds to the α- and γ- phosphates of di- or tri- nucleotides whiles Walker 
B motif helps manage magnesium ions. Walker C (LSGGQ) is a signature to ABC-
transporters and has been proposed to play a role in the dimerization of NDB1 and NDB2 
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[15]. Each MSD contains six transmembrane spanning α-helices [13, 6] which form 
substrate translocation pathway. ABC transporters with at least two MSDs and two NBDs 
are considered full transporters whereas those with one of each domain are known as half 
transporters [17]. MRPs with a four-domain arrangement of two MSDs and two NBDs are 
known as ‘short MRPs’, whiles ABC transporters with an additional NH2-proximal MSD0 
are referred to as ‘long MRPs’ [18] (Figure 1.3). 
 
 
 
Figure 1.3 The predicted topology of long and short MRPs 
Protein backbone is illustrated as thin tubes while transmembrane helices are shown as 
cylinders. A. The predicted topology of the MSDs and NBDs of long MRPs (MRP1, 2, 3, 
6, and 7). B. The predicted arrangement of short MRPs (MRP4, 5, 8, and 9). [18] 
 
B 
A 
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MRP1 has an extra MSD (MSD0) towards the N terminus and comprises of 5 additional 
transmembrane spanning α-helices located on the extracellular side of the membrane. 
MSD0 does not play a role in the efflux activity of the transporter, but it is required for 
efficient retention of MRP1 at the cell surface [19]. The NBDs are directly involved in the 
binding and hydrolysis of ATP [20]. The MSDs provide substrate binding sites and 
contribute to transporter specificity [15, 16]. The binding site of MRP1 is bipartite in 
nature; a positive charged region that binds to GSH moiety (P-pocket) and a large 
hydrophobic area that encompass a lipid tail (H pocket) [23]. This nature enables it to bind 
to a more diverse nature of compounds which ae structurally unrelated.  
The proposed transport mechanism for substrate transport is the ATP switch model by 
Higgon and Linton [22]. According to this model, the NBDs of MRP1 alternate between a 
closed and an open conformation. These movements result in ligand translocation [24]. 
The closed conformation has two ATP molecules bound to the NBD dimer interface 
forming a nucleotide pocket. In the pocket, ATP binds to the Walker A and Walker B 
motifs. Transport is initiated by the binding of substrate to the MSDs in the open NBD 
conformation which increases affinity to ATP [16, 18]. The binding of ATP induces 
changes in the formation of closed NBDs dimer which subsequently induces a major 
conformational change in the MSDs to start substrate transport. ATP hydrolysis occurs 
which causes changes in the NBD dimer dissolution to be transmitted to the MSDs. The 
basal state of transporter is restored with sequential release of inorganic phosphate and 
adenosine diphosphate (ADP) [16, 19]. This substrate transport mechanism was confirmed 
in studies on the binding of LTC4 (MRP1 substrate) to bovine MRP1 (91% identical to 
human MRP1). The binding of LTC4 was shown to bring the NBDs closer and aligned 
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properly. ATP hydrolysis occurs when the two NBDs dimerize to form a complete catalytic 
site. The binding of LTC4 stabilizes the closed conformation where NDBs are properly 
aligned [17, 20]. 
 
1.3 Multidrug resistance in cancer 
Multidrug resistance (MDR) is the resistance of cancer cells to multiple chemotherapeutic 
agents with different structures, targets and mechanism of action. MDR mechanisms can 
be categorized into 7 areas as shown in Figure 1.4. These areas include; (1)increased drug 
efflux by membrane transporters (mainly, ABC transporters); (2) reduction in drug uptake 
by influx transporters (solute carriers); (3) enhanced drug metabolism; (4) blocking 
apoptotic signaling pathways; (5) Gene regulation; (6) mutation in drug targets or feedback 
activation of other targets and signaling pathways; and (7) chemoresistance induced by 
changes in the microenvironment. However, one of the most common mechanism studied 
is increased drug efflux due to the overexpression of ABC transporters [21, 22]. 
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Figure 1.4 Mechanisms of Multidrug resistance in cancer 
[29]  
 
The most studied MDR transporters include P-gp, MRP1 and BCRP [30]. The 
overexpression of these transporters leads to efflux chemotherapeutic agents thereby 
reducing drug accumulation and causing tumor cells to become resistant. The specific 
association between membrane transporters and multidrug resistant phenotype was first 
discovered in the Chinese hamster ovary cell line in the 1970s. This cell line selected for 
resistance to colchicine, was found to also exhibited resistance to daunomycin and 
puromycin [31]. P-gp, a 170 kDa glycoprotein, regulates the export of a wide variety of 
anticancer drugs and other hydrophobic compounds including anthracyclines (doxorubicin, 
daunorubicin), epipodophyllotoxins (etoposide, teniposide), vinca alkaloids (vincristine, 
vinblastine),  taxanes and the cancer imaging agent tetraphenylphosphonium (TPP) [32]. 
Intravenous administered drugs such digoxin, cyclosporine, ivermectin, paclitaxel, 
vinblastine, grepafloxacin, indinavir and nelfinavir  also undergo intestinal excretion 
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mediated by P-gp. P-gp is expressed in normal tissues, such as the epithelium of the 
kidneys, liver, intestine, pancreas, placenta and adrenal gland, where it excretes toxic 
metabolites [33]. It is also located at the apical, mucosal and lumenal surface of epithelial 
cells in organs often involved in drug absorption, distribution and excretion [34]. Literature 
has shown that tumors originating from tissues with naturally high levels of P-gp 
expression may be intrinsically drug resistant (e.g., colon, kidney, pancreas, and liver 
carcinoma) [34]. Several studies have reported the presence of P-gp mRNA and protein in 
clinical samples cancers such as leukemia, kidney, colon, breast, and lung cancers [31,32]. 
The elevated expression of P-gp has been linked to poor response to chemotherapy.  
MRP1, a 190 kDa protein, was first discovered in an anthracycline-resistant cell line 
HL60/Adr [37]. Unlike P-gp, MRP1 is localized at the basolateral membrane of epithelial 
cell layers [68], and thus, it transports substrates towards the basolateral side of the 
epithelia. A significant number of drug substrates of P-gp overlaps with MRP1. MRP1 
confers resistance to a wide range of anticancer drugs such as anthracyclines, vinca 
alkaloids, epipodophyllotoxins, camptothecins, methotrexate (MTX), saquinavir, and 
mitoxantrone (MX); however, in contrast to P-gp, it does not confer resistance to taxanes. 
Taxanes are an important component of the P-gp resistance profile. Although the drug 
resistance profile of MRP1 and P-gp overlaps, their physiological substrate profile differs 
significantly. While substrates for P-gp are neutral or mildly positive lipophilic 
compounds, MRP1 can efflux of a broad array of physiological organic anions such as 
leukotriene C4 (LTC4) and dinitrophenyl-S-glutathione (DNP-SG) [19]. The discovery that 
MRP1 was capable of transporting both conjugated and non-conjugated organic anions 
broadened it pharmacological and physiological relevance. Conjugated xenobiotic organic 
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anions which are produced from phase II metabolism of drugs and GSH conjugated drugs 
are also effluxed by MRP1. It can also transport glucuronate conjugates (e.g., E217βG), 
dianionic bile salts, and sulfate conjugates [28]. 
Clinically, MRP1 has been found to be up-regulated in a variety of solid tumors, including 
those of lung, breast, and prostate [32]. Its expression is a negative prognostic marker for 
early-stage breast cancer [38] and predicts poor response to chemotherapy and decreased 
survival in non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC) 
[28, 29]. NSCLC forms majority of  lung cancer cases and the disease is commonly 
aggressive and chemo-resistant. Interestingly, MRP1 is found to be frequently 
overexpressed in a large percentage of tumors prior to treatment and in the case of prostate 
cancer, the MRP1 levels is known to increase with disease progression [40]. The most 
compelling case for the clinical role of MRP1 in multidrug resistance is the case of 
neuroblastoma where there is a strong association of MRP1 with a negative clinical 
outcome. A retrospective study showed that MRP1 expression was found in 209 
neuroblastoma samples. Multivariate analysis revealed that an increased MRP1 expression 
was highly predictive of a lower relapse free survival and the overall survival of patients 
[41]. The study provided evidence of MRP1 as a strong independent prognostic indicator 
in neuroblastoma. Interestingly, P-gp/ABCB1, expression did not predict clinical outcome 
[41]. This suggests that MRP1, not P-gp, is the primary mode of MDR in neuroblastoma. 
BCRP, a (70 kDa) consisting of a single NBD and MSD, functions as either homodimers 
or homomultimers bridged by disulfide bonds. It was first cloned based on its 
overexpression in a doxorubicin-resistant MCF7 breast cancer cell line (MCF-7/AdrVp). 
BCRP expression is varied among normal tissues with the highest levels found in the 
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placenta. It is also prominently expressed on the apical membrane of the epithelium in the 
small intestine and colon and on the canalicular membrane of hepatocytes [42]. BCRP can 
mediate efflux of doxorubicin, mitoxantrone, topotecan, irinotecan and it active metabolite 
SN38, methotrexate, and tyrosine kinase inhibitors. In addition to hydrophobic substrates 
such as mitoxantrone, BCRP can also transport hydrophilic conjugated organic anions like 
the sulfate conjugates unlike P-gp [43]. BCRP has been found to be overexpressed in 
several tumors, however majority of work has been in the area of acute myeloid leukemia 
(AML). Several studies have shown a positive correlation between high levels of BCRP 
expression and poor clinical outcomes in AML, e.g., a relapsed or refractory disease state, 
lower response rate, shorter overall survival, and/or no complete remission. Other studies 
reported no correlation of BCRP expression with clinical outcomes or no expression of 
BCRP in AML. Factors such as low sensitivity of methods used and the co-expression with 
P-gp and MRP1 in patients with AML has been attributed as the possible reasons of the 
disparities in literature [44]. 
Several in vitro studied have demonstrated that TKIs such as imatinib, nilotinib, and 
dasatinib are modulators of P-gp and BCRP [45]. Clinical studies have also shown a 
correlation between mRNA expression of P-gp and BCRP in peripheral blood leukocytes 
and poor clinical outcomes in 118 chronic-phase CML patients receiving a standard dose 
of imatinib mesylate [46]. BCRP mRNA expression levels were higher in patients who did 
not respond to treatment before and during imatinib therapy. These data suggest that the 
elevated expression of BCRP may be associated with imatinib resistance.  
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1.4 Modulators of ABC transporters 
Ligands which interact with ABC transporters can act as substrates (effluxed by 
transporter), inhibitor (impairs transport of other compounds), inducers (enhance 
transporter protein expression) or activators (enhance transporter activity). The different 
properties and modes of action can be explored for diverse therapeutic use. Inducers and 
activators are not always related as an increase in protein expression may not induce 
increased protein activity [17]. Whiles inducers promote upregulation of transporter, 
activators induce conformational changes which stimulates the transport/efflux of a 
substrate bound to another binding site. Both inducers and activators can be useful in 
conditions where toxicity to target tissues can be reduced due to transporter overexpression. 
Dexamethasone [47], rifampicin [47], sunlinac [48], vinblastine and TBHQ are all inducers 
of MRP1[49]. A compound can have overlapping modes of action. Some substrates can 
act as inhibitors. Generally, it has been much more difficult to find good small molecule 
inhibitors for MRP1 than for P-gp. This may be due to MRP1’s preference for anionic 
compounds as substrates or inhibitors. Most anionic compounds enter cells poorly, thus it 
may be difficult to obtain good intracellular concentrations to aid effective inhibition. A 
variety of inhibitors of MRP1 have been identified including the LTC4 analogue MK571, 
S-decylglutathione, sulfinpyrazone, benzbromarone and probenecid [13, 34, 35]. For 
specific MRP1 in vivo inhibition, general organic anion transporter inhibitors such as 
sulfinpyrazone, benzbromarone and probenecid are not suitable, as they affect organic 
anion uptake systems  in cells. The main challenges with these inhibitors are their broad 
range specificity and cytotoxicity. In order to overcome MRP1 mediated resistance in 
cancer chemotherapy, better MRP1 inhibitors need to be developed, with higher 
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specificity, cellular penetration properties, and low cytotoxicity. The scope of this study 
focuses mainly on identifying inhibitors of MRP1. This work seeks to provide 
methodological alternatives to identify MRP1 inhibitors using high throughput screening 
based on high content imaging.  
 
1.5 In vitro screening methods for evaluating ABC transporter interaction 
Determination of a drug candidate as an inhibitor/substrate of ABC transporters is vital in 
profiling drug-transporter interactions as it helps predict the drug candidate’s 
bioavailability in vivo. Drugs and food nutrients that modulate ABC transporters may also 
affect the bioavailability of a co-administered drug. Generally, in vitro assays are 
categorized as ‘cell-based’ or ‘membrane-based’ depending on whether an assay is 
performed with intact cells or with isolated membranes [51]. Both cell and membrane-
based assays are riddled with their intricate advantages and disadvantages and are 
frequently performed together to verify and validate data derived from each other. Several 
in vitro assays have been developed to probe the interactions between drug candidates and 
these efflux transporters. ABC transporters are also well known to have a broad range of 
substrate specificity, due to the existence of multiple substrate binding sites. Thus, assay 
systems that utilize a single probe compound may not identify all substrates or modulators 
that bind at different binding sites resulting in false negatives. Cost reduction, effective 
prediction of drug-transporter interaction in vivo, and toxicity are areas that need 
improvement in the current systems used. In the following sections, some common in vitro 
assay for studying drug -transporter interactions relevant to this study are discussed.  
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1.5.1 Fluorescence accumulation and efflux assay 
One of the most widely used cell-based assays for assessment of compound interaction 
with ABC transporters is the fluorescent accumulation assay. This assay measures the 
intracellular accumulation of a fluorescent substrate in a transporter-overexpressing cell 
line in the presence or absence of test compounds in order to understand the effect of test 
compounds on transporter activity. The intracellular accumulation of the fluorescent 
substrates is inversely proportional to the transporter activity and can be measured by 
fluorescence spectrophotometry. Thus, an increased intracellular accumulation of a given 
substrate (higher intracellular fluorescence) can be observed in the presence of an inhibitor, 
while the opposite (decreased intracellular accumulation) occurs in the presence of an 
inducer or activator. Discrimination between an inducer or activator is dependent on the 
incubation period with the test compounds. Activators need lesser time period to elicit their 
effect as they only induce conformational changes whiles inducer need extended incubation 
time period with drugs as de novo synthesis of transporter is needed. Generally, assays 
using a fluorescent probe to track transporter activity are also termed the dye extrusion 
assay or the uptake assay [52]. 
In efflux studies, however, the amount of fluorescent substrate in the extracellular 
environment of cells is measured under various conditions known to influence the 
transporter activity. Cells are preloaded with the substrate of interest in the presence of an 
inhibitor of the efflux transporter, the amount of fluorescent substrate expelled from the 
cells will be less than that observed for cells without inhibitor. In contrast, the amount of 
fluorescent substrate expelled will be greater in the presence of an inducer or activator. 
This method is thus based on the altered accumulation and efflux of a fluorescent substrate. 
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The analysis of the efflux activity of transporters may be based on the evaluation of the 
fluorescence accumulation, efflux or both.  
Table 1.1 shows a list of common fluorescent substrates used for studying drug transporter 
interactions. Detection and quantification of the intracellular accumulated fluorescent 
substrate is commonly determined by flow cytometry. Quantitative measurements of the 
differences in fluorescence levels between non-treated control and drug treatments are thus 
used for inferences and analysis. Therefore, test compound that exhibit inherent 
fluorescence at the emission similar to that of the fluorescent substrate used can interfere 
with quantification. As such, it is important to inspect the background fluorescence of 
individual test compounds.
16 
 
Table 1.1 Fluorescent substrates for ABC transporter assays  
 ABCB1 
(Pgp) 
ABCC1 
(MRP1) 
ABCG2 
(BCRP) 
REFERENCES 
Fluorescent probe 
Green/FITC 
BODIPY FL EDA    [53]  
BODIPY FL Forskolin    [53]  
BODIPY FL Histamine    [53] 
BODIPY FL Prazosin    [54]  
BODIPY FL Thapsigargin    [53] 
BODIPY FL Verapamil, HCl    [53] 
BODIPY FL Vinblastine    [55],  
Calcein AM    [56], [57]  
CBIC2(3) (JC-1)    [58], [59],  
DiNOC1(3) (JC-9)    [53] 
DiOC2(3)    [60]  
DiOC5(3)    [53] 
DiOC6(3)    [61]  
eFluxx-ID Green    [62]  
ER-Tracker Green    [53] 
MitoTracker Green FM    [53] 
Phengreen diacetate    [63]  
Rhodamine 123    [57], [64]  
SYTO 13    [53] 
SYTO 16    [53] 
SYTO 9    [53] 
Yellow/PE 
Alexa Flour 555 hydrazide    [53] 
Alexa Fluor 532, 594, 546 C5- 
maleimide 
   [61] 
CellTracker Orange CMTMR    [53] 
eFluxx-ID Gold    [62]  
MitoTracker Orange CMTMRos    [53] 
Rhodamine 6G chloride    [53] 
Rhodamine B, hexyl ester, 
perchlorate (R6) 
   [53] 
TMRE    [53] 
Red 
DiIC1(5)    [53] 
Doxorubicin    [65], [66], [60]  
Mitoxantrone    [67], [66]  
Pheophobide A    [68], [69] 
DAPI/ Blue 
Dyecycle violet (DCV)    [70], [63]  
Orange 
Tetramethylrosamine Chloride    [71], [53] 
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1.6 Traditional membrane-based assays 
1.6.1 Inside-out Membrane Vesicles 
Membrane vesicles prepared from cells expressing ABC transporters are a valuable tool 
for studying ABC transporter activities. Membrane vesicle preparation exposes the 
substrate-binding site of ABC transporters and allows better identification of certain classes 
of compounds due to matrix simplification of the vesicles. Membrane vesicles can be 
prepared from various sources such as intestinal brush border membranes, hepatic 
sinusoidal and canalicular membranes, encephalic luminal and abluminal membranes, and 
any transporter-expressing cell lines[72]. Cell lines engineered to overexpress individual 
transporters are especially useful for the evaluation of specific interactions between the 
transporter and compounds of interest. Vesicular transport studies using various types of 
membranes from different sources (insect cells [10], transfected [73] or selected [74] 
mammalian cell lines and artificial membrane vesicles [75] have been reported. 
Mammalian HEK293 and insect Sf9 membrane vesicles expressing ABC transporters are 
widely used as a screening tool in drug discovery [10] and are commercially available. The 
preparation of membrane vesicles involves the disruption of cells or tissues and the 
collection of the membrane fraction through ultracentrifugation. Three types of membrane 
formations can exist in a crude membrane preparation: lamellar, inside-out, and right-side-
out (Figure 1.5) [73].  
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Figure 1.5 Various orientation of crude membrane vesicle 
A. Membrane vesicles formed inside-out. Further enrichment of crude membrane vesicle 
can increase their percentage. B. Membrane vesicles in open lamellar configuration. C. 
Membrane vesicles in right side-out configuration. 
 
In the membrane vesicular transport assay investigating efflux transporters, only inside-out 
vesicles contribute to the trapping of target substrates, so it is desirable to enrich vesicles 
with the inside-out orientation. Traditionally, low ionic strength buffer devoid of bivalent 
ions has been used to achieve this. Nitrogen cavitation is another feasible method for 
promoting the formation of inside-out vesicles in the crude membrane preparation [57, 9]. 
Purification of crude membrane using methods such as sucrose gradient centrifugation [58, 
59] and concanavalin-A chromatography [75] can further enrich the concentration of 
inside-out vesicles [73]. Once the membrane vesicles are generated, they are relatively 
stable and can be stored at -80 °C for many months [73]. Membrane vesicles are also ideal 
for studying ABC transporter kinetics.  
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1.6.2 Membrane vesicular transport 
The membrane vesicular transport assay is based on the ATP-dependent transport of a 
substrate into the inside-out membrane vesicles. It was the first in vitro assay developed 
for ABC transporter studies when Horio et al. used membrane vesicles prepared from a 
cancer cell line to detect the ATP-dependent transport of vinblastine by ABCB1 [76]. To 
date, it is commonly employed for the determination of transporter substrates and 
inhibitors, especially in a high throughput format [59, 42]. Recently, this assay has been 
coupled with targeted metabolomics for the identification of endogenous ABC transporter 
substrates present in bodily fluids, a novel approach termed ‘transportomics’ [62, 41].  
Functionally, the membrane vesicular transport assay can be performed in a ‘direct’ or an 
‘indirect’ (inhibition) setup [51]. In the direct setup, the transport of a compound of interest 
into the membrane vesicles is measured directly, enabling the identification of a substrate-
type relationship with a given transporter. This setup, however, requires each test 
compound to be labeled or analyzed with sensitive analytic methods such as LC-MS/MS, 
making it rather costly for screening purposes. Furthermore, the direct setup is not robust 
in terms of identifying substrates with medium-to-high membrane permeability as they 
diffuse out of the membrane vesicles, resulting in false negative hits [72]. As a result, the 
direct setup is typically used for studying transport of compounds with low membrane 
permeability such as methotrexate, bile acids, and sulfate and glucuronide conjugates of 
various phytoestrogens [62, 41, 63, 64, 65, 66]. The indirect setup, on the other hand, 
examines the inhibitory effect of a test compound on the transport of a reporter substrate. 
Because only the reporter substrate needs to be labeled and/or analyzed, the indirect setup 
is well-suited for high throughput screening of compound-transporter interactions. As a 
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caveat, this setup will not provide information on whether  the test compound is a substrate 
of the transporter being studied. 
The quantity of the transported unlabeled molecules can be determined by HPLC, LC/MS, 
LC/MS/MS. Alternatively, the compounds are radiolabeled, fluorescent in nature or have 
a fluorescent tag so that the radioactivity or fluorescence retained on the filter can be 
quantified. Table 1.2 gives a list of common radiolabeled substrates used for transporter 
studies.  
The vesicular transport assay can also be performed in an "indirect" set-up, where 
interacting test drugs modulate the transport rate of a reporter compound [53]. This assay 
type is particularly suitable for the detection of possible drug-drug interactions and drug-
endogenous substrate interactions. This assay format is not sensitive to the passive 
permeability of the compounds and therefore detects all interacting compounds. However, 
being an indirect method, it will not give information on whether the compound tested is 
an inhibitor of the transporter or a substrate of the transporter inhibiting its function in a 
competitive fashion.  
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Table 1.2 Commonly used radiolabeled substrates for transport assays 
 
 
1.7 Current/alternate methods for assessment of compound interactions 
Relatively new assays are currently available for high-throughput screening of compound 
interaction with ABC transporters. Although not as widely used, they offer unique 
advantages over the abovementioned traditional assay systems. Some of these new assays 
Radiolabeled substrate TRANSPORTER REFERENCES 
[14C]-1-Chloro-2,4-Dinitrobenzene ([14C]-) (CDNB) MRP1, MRP2 [80],  
[14C]-2-Amino-1-Methyl-6-Phenylimidazo[4,5-b] Pyridine ([14C]-
PhIP) 
 
BCRP, MRP2 [82] 
[3’,5’,7’-3H(n)]-Methotrexate MRP2, MRP4 [83]  
[3H] Estradiol 17-(β-d-Glucuronide) ([3H]-E217βG) BCRP [51]  
[3H]-Daunorubicin P-gp, MRP1 [84]  
[3H]-Docetaxel MRP2 [85]  
[3H]-Etoposide MRP2, BCRP [86], [87]  
[3H]-Leukotriene C4 ([3H]-LTC4) MRP1 [81]  
[3H]-Methotrexate BCRP [79] 
[3H]-Mitoxantrone BCRP [79]  
[3H]-Paclitaxel P-gp, MRP2 [61], [88] 
[3H]-Vinblastine MRP2 [88] 
[6,7-3H] Estradiol 17-(β-d-Glucuronide) ([3H]-E217βG) MRP1, MRP2, 
MRP3, MRP4 
 
[88], [89]  
[7-methoxy-3H]-Prazosin BCRP [90]  
[G-3H]-Digoxin P-gp [57]  
[G-3H]-Vinblastine Sulfate P-gp [91]  
[ring C, methoxy-3H]-Colchicine P-gp [57] 
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include high content imaging, bioluminescent imaging, fluorescence resonance energy 
transfer (FRET), and antibody binding shift assay. For the scope of this study we will focus 
mainly on high content imaging. 
 
1.7.1 High Content Imaging 
In recent years, imaging-based high content screening (HCS) using an automated 
microscope platform has gained increasing popularity in drug discovery and biomedical 
research. HCS allows high-throughput imaging of single or multiple biological activities 
measured as intensity or spatial localization of fluorescent dyes or proteins in cells or whole 
organisms. HCS platform offers unique advantages over traditional high throughput 
screening (HTS). The major advantage is the ability to provide multiple readouts. The 
readout is typically a fixed endpoint based on object segmentation, which minimizes 
background noise and facilitates automated analysis.  
HCS methods have been used to investigate compound interactions with P-gp and BCRP. 
Ansbro et al. screened a kinase inhibitor library for P-gp inhibitory activity with an uptake 
assay using multidrug-resistant P-gp-overexpressing KB-V1 carcinoma cells and the 
parental KB-3-1 cells with calcein AM as the fluorescent probe [92]. Phase-contrast and 
fluorescent images were acquired which allowed for segmentation masks. This helped 
identify individual cells constructed based on phase-contrast images and used for the 
quantification of intracellular fluorescence intensity[92]. Using the HCS platform, several 
P-gp modulators were identified. The assay also provides greater sensitivity over plate 
reader, which is more suitable for homogeneous assay. We recently set up an uptake assay 
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for studying compound interaction with MRP1 using a similar method [93]. Example for 
cell segmentation is shown in Figure 1.5. An additional, advantage of HCS is that unlike 
assays using a flow cytometer, cells can be imaged in situ without the need of preparing 
cell suspension and performing multiple washing steps, which increase the processing time 
and limit the assay throughput. Furthermore, cell viability and density before and after 
treatment can be visually inspected in bright-field or phase-contrast images. This assists in 
the evaluation of compound cytotoxicity, which may interfere with the assay. 
 
 
Figure 1.6 Example of high content images and segmentation 
[93] 
 
The examples discussed above improve the sensitivity and processing time of traditional 
uptake assay. However, HCS platform can offer additional analysis capability studying 
multiple functions simultaneously. In a recent study conducted by Antczak et al., an HCS 
platform was used to simultaneously investigate BCRP-inhibitory and cytotoxicity of test 
compounds [94]. Using human glioblastoma cell line U87MG stably expressing BCRP, 
uptake of a fluorescent BCRP substrate, JC-1 (J-aggregate–forming lipophilic cation 
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5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethyl benzimidazole carbocyanine iodide), after a 16-h 
incubation was used to probe compound inhibition of BCRP, while Hoechst accumulation 
in the nuclei was used to reflect cell number, which indicates cytotoxicity of test 
compounds. 
 
1.8 Rationale of Study 
ABC transporters are involved with the uptake of small molecules thus recognized as the 
key drug transporters for assessment in the drug discovery and development process. This 
recommendation was made by the International Transporter Consortium (ITC), a team of 
experts in pharmacology and pharmaceutical sciences from academia, industry, and the US 
Food and Drug Administration (FDA) in 2007 [10]. Currently, recommendations for the 
appropriate in vitro and in vivo studies for drug-transporter interaction are only available 
for ABCB1 (MDR1) and ABCG2 (BCRP) [60]. We anticipate that with an increased 
appreciation for the relevance of ABC transporters, interactions between drug candidates 
and ABC transporters will become a routine assessment. 
Drug discovery and development is an intricate, time-consuming, and costly process. The 
cost of successfully developing an approved drug from a new molecular entity (NME) is 
estimated to be between $800 million and $1.2 billion, with a development timeline of 8–
12 years [95]. Between 2007 and 2010, the combined success rate at Phase III clinical trial 
and submission fell to approximately 50%, with major causes of attrition being lack of 
efficacy and safety issues [96]. In Phase II clinical trials, apart from strategic failures, lack 
of efficacy, safety issues, and unfavorable bioavailability are reasons drug candidates fail 
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[97]. As the key efflux transporters regulating the absorption, distribution, metabolism, 
excretion, and toxicity (ADMET) of xenobiotics, ABC transporters can influence the 
bioavailability and toxicity of a substrate drug through direct efflux, drug-drug and drug-
nutrient interaction (DDI and DNI) [10], [98]. Efflux by ABC transporters in organs such 
as intestines, livers, and target organs can limit the bioavailability of drugs, resulting in 
sub-therapeutic concentrations of drugs [98]. Conversely, the efflux activity of ABC 
transporters can be crucial in liver toxicity [98]. Considering the importance of ABC 
transporters in determining drug absorption, disposition, and toxicity, there is a need for 
profiling the interactions of leading drug candidates with ABC transporters.  
Developing high content screening assays for ABC transporters may provide an effective 
pathway against drug-induced toxicity. With new test compounds and pharmacological 
libraries being developed against a wide range of diseases, it is important to develop 
screening methods with high specificity and reliability for identifying modulators of ABC 
transporters especially for transporters that are implicated in multidrug resistance 
phenotype (P-gp, MRP1, and BCRP). The use of just one traditional in vitro screening 
method is fraught with challenges such as the possibility of false negative results because 
of the relatively low sensitivity of these methods. 
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Doxorubicin as a Fluorescent Reporter Identifies Novel MRP1 (ABCC1) Inhibitors 
Missed by Calcein-Based High Content Screening of Anticancer Agents  
 
Abstract 
Multidrug resistance protein 1 (MRP1/ABCC1) actively transports a variety of drugs, toxic 
molecules and important physiological substrates across the plasma membrane. It can 
confer broad-spectrum multidrug resistance and can decrease the bioavailability of many 
important drugs. Substrates of MRP1 include anti-cancer agents, antibiotics, antivirals, 
antidepressants and anti-inflammatory drugs. Using calcein as a fluorescent reporter in a 
high content efflux assay, we recently reported the identification of 12 MRP1 inhibitors 
after screening an anti-cancer library of 386 compounds. Here, we describe the 
development of a new high content imaging-based efflux assay using doxorubicin as a 
fluorescent reporter. Screening the same anti-cancer library of 386 compounds, the new 
assay identified a total of 28 MRP1 inhibitors including 16 inhibitors that have not been 
previously reported as inhibitors of MRP1. Inhibition of MRP1 activity was confirmed 
using flow cytometry, confocal microscopy and membrane vesicle-based transport assays. 
Six drugs (afatinib, celecoxib, doramapimod, mifepristone, MK-2206 and rosiglitazone) 
were evaluated for their ability to reverse resistance of MRP1-overexpressing H69AR lung 
cancer cells against vincristine, doxorubicin and etoposide. Mifepristone and doramapimod 
were most effective in reversal of resistance against vincristine while mifepristone and 
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rosiglitazone were most successful in resensitizing H69AR cells against doxorubicin. 
Furthermore, resistance towards etoposide was completely reversed in the presence of 
celecoxib or doramapimod. Selected drugs were also evaluated for resistance reversal in 
HEK cells that overexpress P-glycoprotein or breast cancer resistance protein. Our results 
indicate mifepristone and doramapimod as pan inhibitors of these three drug transporters 
while celecoxib exhibited selective MRP1 inhibition.  Together, our findings signify the 
importance of MRP1 in drug discovery and demonstrate the effectiveness and value of 
doxorubicin-based high content screening approach. Anti-cancer agents that exhibit MRP1 
inhibition may be used to reverse multidrug resistance or to improve the efficacy and 
reduce the toxicity of various cancer chemotherapies. On the other hand, anti-cancer drugs 
which did not interact with MRP1 carry low risk for developing MRP1-mediated 
resistance.  
 
Keywords: MRP1; ABCC1; ABC transporter; multidrug resistance; MRP1 inhibitors; drug 
absorption and disposition; high content screening; anti-cancer agent; drug-transporter 
interactions; doxorubicin; drug profiling 
1) Afatinib (PubChem CID: 10184653); 2) Alisertib (PubChem CID: 24771867); 3) 
Alvespimycin (PubChem CID: 5288674);; 4) Amuvatinib (PubChem CID: 11282283); 5) 
Celecoxib (PubChem CID: 2662); 6) Doramapimod (PubChem CID: 156422); 7) 
Flavopiridol (PubChem CID: 5287969); 8) GSK2126458 (PubChem CID: 25167777); 9) 
GSK461364 (PubChem CID: 15983966); 10) GW4064 (PubChem CID: 9893571); 11) 
LY2228820 (PubChem CID: 11570805); 12) LY294002 (PubChem CID: 3973); 13) 
Mifepristone (PubChem CID: 55245); 14) MK-2206 (PubChem CID: 24964624); 15) 
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NVP-BSK805 (PubChem CID: 57339395); 16) OSI-420 (PubChem CID: 18924996); 17) 
Rosiglitazone (PubChem CID: 77999); 18) Saracatinib (PubChem CID: 10302451) 
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1.0 Introduction 
Cancer is the second leading cause of death worldwide  with  8.8 million deaths occurring 
in  2015 and an estimated 20 million new cases expected annually till 2025 [1, 2]. 
Combinatorial therapeutic approach of using multiple cytotoxic drugs for cancer treatments 
has led to improvements in survival rates for various types of cancers [3] . However, the 
emergence of drug resistance in tumor cells in many cancers over the years have been a 
challenge to treatment. Tumor cells when exposed  to  cytotoxic drugs can develop cross-
resistance to a wide range of compounds [4, 5]. This phenomenon, known as multidrug 
resistance (MDR) makes tumors unresponsive to a variety of drugs irrespective of their 
differences in structure and molecular targets [3] and can lead to failure in chemotherapy. 
Conventional chemotherapeutic drugs such as doxorubicin, vincristine, actinomycin-D, 
and paclitaxel have been previously shown to induce MDR [6].  
Development of resistance is a major obstacle in the success of chemotherapy. MDR is 
reportedly responsible for over 90% of chemotherapy failures of metastatic cancers 
involving surgery or radiation [7]. MDR can be acquired through various mechanisms such 
as alteration of drug target, decreased drug absorption, increased drug efflux, increased cell 
repair activity, alteration in lipid membrane composition and altered cell cycle check points 
[3, 7]. However, the overexpression of ATP-binding cassette (ABC) drug efflux 
transporters is the most frequent mechanism of MDR and is widely studied [3, 8, 9, 10]. A 
total of 48 ABC transporter genes have been reported in the human genome and they are 
grouped into seven subfamilies, designated A-G [11]. In particular, ABC drug transporter 
proteins such as P-glycoprotein (P-gp/ABCB1), multidrug resistance protein 1 
(MRP1/ABCC1) and breast cancer resistance protein (BCRP/ABCG2) are frequently 
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upregulated in cancer [12, 13]. These drug transporters actively pump out 
chemotherapeutic drugs reducing the intracellular levels of drugs and thereby attenuating 
their cytotoxic actions. 
The prototypical eukaryotic ABC proteins have a four-domain core structure, containing 
two hydrophobic membrane-spanning domains (MSDs) and two nucleotide-binding 
domains (NBDs) that are cytosolic [14, 15]. Structural studies of the ABC transporter 
proteins revealed that the two cytosolic NBDs coordinate in a head-to-tail orientation to 
form a “sandwich” dimer that generates two composite nucleotide binding sites. 
Furthermore, the two membrane-spanning domains are intertwined to form the substrate-
binding site/s and the substrate translocation pathway and extend into the cytoplasm 
making contacts with the NBDs. The binding and hydrolysis of ATP which is coupled to 
substrate binding provides the energy required for the transport process [16]. The structure 
of MRP1 and several “C” subfamily members contain an additional MSD at the amino-
terminus of the protein, whose specific biological role is poorly understood. 
MRP1 is an integral membrane protein that functions as an ATP-dependent drug efflux 
pump. It localizes at the plasma membrane and can efflux a wide variety of endogenous 
and exogenous substrates including toxic chemicals, drugs and their metabolites out of 
cells. Overexpression of MRP1 can confer resistance against commonly used cytotoxic 
anti-cancer agents like doxorubicin, vincristine, methotrexate and etoposide. MRP1-
overexpression has been associated with MDR of several types of cancers in clinics. In 
addition to anti-cancer agents, MRP1 can reduce the efficacy of many commonly used 
drugs including antibiotics, antivirals, antidepressants, anti-inflammatory and anti-HIV 
drugs [8, 9, 10, 17, 18] Therefore, MRP1 is considered an important therapeutic target and 
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may be used to improve the efficacy of various therapies including cancer chemotherapy. 
On the other hand, MRP1 plays an important role in tissue defense and in regulation of 
various biochemical processes such as redox homeostasis, steroid metabolism, lipid 
metabolism, and the etiology of neurodegenerative, immunological, and cardiovascular 
pathologies [19, 20]. It effluxes a remarkable variety of xenobiotics and organic anions 
from endogenous sources, which are mostly conjugated to glutathione, glucuronide, or 
sulfate. Physiological substrates of MRP1 include organic anions such as cysteinyl 
leukotriene (LTC4), estradiol glucuronide (E217βG), glutathione (GSH), and cobalamin. 
Automated fluorescence imaging-based high content screening platform is becoming very 
popular in drug discovery and development research due to its capability to provide high 
resolution in situ visual data that allows to simultaneously study multiple phenotypes. We 
have recently demonstrated the development and validation of a high content imaging-
based efflux assay using calcein-green as a substrate reporter of MRP1 transport activity 
[9]. Using this assay in screening a unique library of 386 anti-cancer compounds, we 
identified a total of 12 inhibitors of MRP1 that included 10 novel inhibitors not previously 
reported to interact with MRP1. Doxorubicin, a cytotoxic anti-cancer drug, is a well-known 
substrate of MRP1 and P-gp. However, it has not been successfully used in high-throughput 
screening assays using flow cytometry or fluorescent microplate reader-based 
methodologies likely due to its dimness and relatively poor affinity for the transporter 
protein. Due to the polyspecificity and the promiscuous nature of MRP1 substrate binding, 
we hypothesized that doxorubicin-based screening assay may identify novel inhibitors of 
MRP1. In this study, we describe the development, optimization, and validation of a high 
content imaging-based efflux assay using doxorubicin as a fluorescent reporter substrate. 
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The value and effectiveness of this assay is demonstrated by screening the library of 386 
anti-cancer drugs. The screening process identified a total of 28 inhibitors, which included 
10 of 12 inhibitors discovered previously with calcein-green assay as well as 18 MRP1 
inhibitors that were missed by the calcein-based screening. We verified the inhibitory 
activity of the identified compounds using established methods and discovered 16 
compounds that have not been previously known to inhibit MRP1. The ability of some 
selected compounds to reverse the resistance of an MRP1-overexpressing MDR cancer cell 
line is also demonstrated.  
 
2.0 Materials and methods 
2.1 Chemicals  
Doxorubicin, adenosine monophosphate (AMP), adenosine triphosphate (ATP), estradiol 
17-(β-D-Glucuronide) (E217βG), poly-D-lysine, thiazolyl blue tetrazolium bromide 
(MTT) were procured from Sigma-Aldrich (St. Louis, MO). MK571 was acquired from 
Cayman Chemical (Ann Arbor, MI) and [6,7-3H]E217βG (49.9 Ci mmol–1) from 
PerkinElmer (Waltham, MA).  Anti-cancer compound library consisting of 386 anti-cancer 
small molecules under clinical trials for 12 different types of cancers was procured from 
Selleck Chemicals (Houston, TX). 
2.2 Cell lines and cell culture 
H69 and H69AR cells were purchased from ATCC (Manassas, VA). HEK293T cells were 
kindly provided by Dr. Adam Hoppe (South Dakota State University, Brookings, SD) 
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while HEK293/pcDNA3.1, HEK293/BCRP and HEK293/P-gp (MDR1) were a kind gift 
from Dr. Suresh V. Ambudkar (NIH, Bethesda, MD). HEK293 and H69 cell lines were 
cultured in DMEM (GE Healthcare, Marlborough, MA) and RPMI 1640 (ATCC), 
respectively, supplemented with 10% fetal bovine serum. Cells were grown in a humidified 
incubator maintaining 5% CO2 at 37 °C. H69AR cells were exposed to 0.8 µM doxorubicin 
once a month and cultured drug-free for a week before use. 
 
2.3 MRP1 inhibition screening with automated image acquisition and analysis 
Assay development and optimization were performed with H69 and H69AR cells with 
doxorubicin as the fluorescent substrate and MK-571 as the positive inhibition control. 
Cells were seeded at 6 × 104 cells per well in 100 µL culture medium in 96-well optical-
bottom plates with polymer base (Thermo Fisher Scientific, Waltham, MA) coated with 
poly-D-lysine (Sigma-Aldrich, St. Louis, MO) and incubated overnight. Culture medium 
was removed prior to drug treatment and replaced with 80 µL of serum-free medium. For 
pretreatment, 10 µL of test compounds (10 µM final concentration), DMSO (0.2% final 
concentration) as negative control, or MK-571 (50 µM final concentration) as positive 
control were added. Following the 30 min incubation, 10 µL of doxorubicin (10 µM final 
concentration) was added and the cells were incubated for 2 h. At the end of the incubation 
period, treatment was removed, cells were rinsed once and 100 µL of PBS containing 
10mM HEPES and 4.5% glucose was added.  
Images were obtained using an ImageXpress Micro XLS Widefield High-Content Analysis 
System (Molecular Devices, Sunnyvale, CA) equipped with a 0.70 numerical aperture 60× 
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objective. A total of 8 images (4 bright field and 4 fluorescent) were taken for each well. 
Fluorescent images were acquired using a texas red filter with excitation and emission 
wavelengths of 562/40 nm and 624/40 nm, respectively, with an exposure time of 100 ms. 
As the intracellular accumulation of doxorubicin slowly dropped over time, a negative and 
positive control were included in every two columns. Screening experiments were 
performed three independent times. Fluorescent images were analyzed using the 
MetaXpress software (version 5.10.41, Molecular Devices). Segmentation of fluorescent 
objects on the texas red channel was done using a custom application module based on the 
‘Find Blobs’ module. The custom module differentiates fluorescent accumulation from 
background and artifacts by applying segmentation masks based on set parameters for 
object size. 
 
2.4 Flow cytometry-based doxorubicin accumulation assay  
Flow cytometry was used to confirm the ability of drugs to inhibit MRP1 mediated efflux 
of doxorubicin. H69AR cells were prepared in serum-free culture medium to a density of 
7 × 105 cells/mL. For this assay, 1 mL of cells were incubated with test compounds (10 
µM) at 37 °C for 1 hour after which 10 µM of doxorubicin was added for an additional 2 
hours. Total DMSO concentration was maintained at 0.2% (v/v). Efflux activity of MRP1 
was stopped by the addition of ice-cold PBS buffer. Cells were then collected, washed with 
cold PBS and resuspended in ice-cold PBS containing 1% formaldehyde. Intracellular 
fluorescence of doxorubicin was detected by BD Accuri C6 flow cytometer (BD 
Biosciences, San Jose, CA) equipped with 488nm and > 670nm for excitation and emission 
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respectively. Fluorescence intensity was collected as mean of 10,000 events. Treatments 
were performed in duplicate and repeated in 3 independent experiments.  
 
2.5 Doxorubicin accumulation assay using confocal microscopy 
HEK293T cells were plated on poly-D-lysine-coated cover glass placed in a 6-well plate 
at a density of 5 × 105 cells/well in 2 mL culture medium. Cells were transiently transfected 
with an MRP1-GFP expression vector after 24 hours using jetPRIME Transfection Reagent 
(Polyplus-transfection SA, Illkirch, France) according to the manufacturer’s protocol. 
After 48 hours, cells were pre-treated with 10 µM test compound for 30 min, before 
incubation with doxorubicin (10 µM) for 1 h. Cells were maintained in buffer (4.5 % 
glucose, 10mM HEPES, PBS containing Ca2+ and Mg2+) as intracellular fluorescence was 
visualized using an iMIC digital microscope (TILL Photonics GmbH, Gräfelfing, 
Germany) equipped with a 1.35 numerical aperture 60x oil-immersion objective. 
Excitation was done at 488 nm for GFP and doxorubicin, with emission bands of 475/42 
and 605/64 nm, respectively. Images were processed using ImageJ (NIH, Bethesda, MD). 
 
2.6 Membrane vesicle preparation  
Membrane vesicles were prepared as described in [21] with modifications. Frozen cell 
pellets of HEK293/pcDNA 3.1 and HEK293/MRP1 were thawed and suspended 
containing 50 mM Tris.HCl, pH 7.4, 250 mM sucrose, 0.25 mM CaCl2, and 1x complete 
protease inhibitors (Santa Cruz Biotechnology, Dallas, TX). Cell disruption was achieved 
via nitrogen cavitation at 450 psi for 5 min. The resulting lysates were supplemented with 
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1mM EDTA and centrifuged at 500 × g at 4 °C for 10 min. The supernatant was collected 
twice by resuspending cell pellets and repeating centrifugation.  Pooled supernatant was 
layered over 35% (w/w) sucrose containing 10 mM Tris.HCl, pH7.4, and 1 mM EDTA and 
centrifuged at 25,000 rpm at 4 °C for 1 h in a SW28 rotor (Beckman Coulter, Brea, CA). 
The opaque membrane interface formed was collected and washed twice by 
ultracentrifugation. The membrane pellet obtained was further resuspended in transport 
buffer (50 mM Tris.HCl, pH 7.4, and 250 mM sucrose) and passed 20 times through a 27-
gauge needle for vesicle formation. Protein concentration was determined using Quick 
Start Bradford Protein Assay (BioRad, Hercules, CA). 
 
2.7 Membrane vesicular transport assay 
A rapid filtration technique was used to measure the ATP-dependent transport of 
[3H]E217βG  into MRP1 enriched inside-out membrane vesicles [22].  The vesicles (2 µg 
protein) were incubated with 400 nM/20 nCi [3H]E217βG for a minute at 37°C in a 30-µL 
reaction mixture containing 4 mM AMP or ATP, 10 mM MgCl2, and test compound in 
transport buffer (250 mM sucrose and 50 mM Tris-HCl, pH 7.4). Total DMSO 
concentration was kept at 0.29%. Reaction was stopped by the addition of ice-cold buffer 
and resulting mixture transferred to a 96-well MultiScreenHTS-FB plate (EMD Millipore, 
Billerica, MA). Filter membranes were washed 4X with 200 µL ice-cold suspension buffer 
under vacuum aspiration.  Radioactivity retained on the membranes was measured using a 
Tri-Carb 4810TR liquid scintillation counter (PerkinElmer, Waltham, MA). ATP-
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dependent uptake was calculated by subtracting the uptake measured in the presence of 
AMP from the uptake in the presence of ATP. Treatments were performed in triplicates. 
2.8 Drug sensitivity assay 
The sensitivity of H69 and H69AR cells towards multiple chemotherapeutic drugs 
(vincristine, doxorubicin, etoposide) and the ability of test compounds to reverse the 
resistance of H69AR cells against these drugs were analyzed using the MTT colorimetric 
assay. The sensitivity of  HEK293, HEK293/BCRP and HEK293/P-gp towards 
mitoxantrone and vincristine respectively was also tested. H69 and HEK293 cells were 
seeded in 96-well plates (CellBIND®, Corning) at 2.5 × 104 and 5 × 103 cells per well in 
100 µL culture medium. After 24 h, cells were pretreated with 50 µL of test compounds in 
culture medium and incubated for an hour. An additional 50 µL of cytotoxic drugs 
(vincristine, doxorubicin, etoposide or mitoxantrone) at varying concentrations was then 
added to the cells. Final DMSO concentration was maintained at 0.2%. Cells were further 
incubated for 96 h (H69 cell lines) or 72 (HEK293 cell lines). At the end of the incubation 
period, 100 µL of culture medium was carefully removed and cells were treated with MTT 
(0.5 mg/mL) for 4 h. The formazan crystals were dissolved by the addition of 100 µL of 
15% SDS containing 10 mM HCl and absorbance at 570 nm were recorded using a Hidex 
Sense Beta Plus plate reader (Turku, Finland). Treatments were performed in triplicate. 
 
2.9 High content screening data analysis  
The MetaXpress software was used for analysis. The software derives the mean fluorescent 
intensity of each well from averaging the fluorescent intensities of the segmentation mask 
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of 4 captured images. The use of segmentation mask prevents the inclusion of background 
fluorescence. The relative inhibition of each test compound on doxorubicin efflux was 
determined for each well using the following equation:  
 , 
where X represents the average fluorescent intensities and T represents the test compound. 
Both positive and negative controls were placed in every two columns and used for the 
determination of the percent inhibition for compounds within the same columns. The Z’-
factor, a parameter commonly used to infer the versatility and variation of an assay [23] 
was determined with the following equation: 
, 
where σ and μ represent the standard deviations and means, respectively.  
 
2.10 Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics (IBM, Armonk, NY). The 
differences between mean values were analyzed using linear mixed model analysis. Dunnet 
correction was applied for multiple comparisons. For all analyses, differences were 
considered significant at P value lower than 0.05. 
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3.0 Results 
3.1 Assay development and optimization 
Calcein-AM, a well-known substrate for MRP1 and P-gp, is commonly used to study the 
activity of these transporters in cell-based assays. We recently reported the development 
of an imaging-based high-throughput efflux assay for MRP1 using calcein-AM in high 
content screening system which offers a much more robust and efficient system compared 
to a fluorescent microplate reader or flow cytometer [9]. Doxorubicin, a fluorescent 
compound and a well-known substrate of MRP1 and P-gp, is a very commonly used 
cytotoxic chemotherapeutic agent for various types of cancer. However, due to its 
relatively low affinity for MRP1 and P-gp the efflux assay produces a very narrow dynamic 
range between positive and negative controls. In addition, high non-specific background 
fluorescence gives many false hits and has not worked well for MRP1 inhibitor screening 
using fluorescence intensity-based microplate reader method. Consequently, doxorubicin 
has not been successfully used as a substrate reporter in high-throughput efflux assays. 
Here, High-Content Screening System which contains advance image analysis and 
quantitation tools was used to develop an imaging-based high-throughput efflux assay for 
MRP1 using doxorubicin as a fluorescent substrate reporter. We used parental H69 cell 
line and its MRP1-overexpressing derivative H69AR cell line for the development of this 
assay. The basic idea is that H69 cells are expected to show higher levels of fluorescence 
due to very low expression levels of endogenous MRP1 and other transporters capable of 
effluxing doxorubicin. In contrast, H69AR cells over-expressing MRP1 will show much 
lower fluorescence accumulation under similar experimental conditions due to active 
doxorubicin efflux. 
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Fluorescent intensities of images were quantified using the ‘Find Blobs’ option in the 
custom module of the MetaXpress software. Cells were identified using object 
segmentation in the texas red channel. To develop and optimize the assay conditions, both 
time and concentration dependent accumulation of doxorubicin in H69 and H69AR cells 
were studied. As shown in Fig. 2.1A, increased concentrations of doxorubicin yielded an 
increase in intracellular fluorescence in both cell lines. However, intracellular 
accumulation of doxorubicin was much higher in the parental H69 cells as compared with 
MRP1-overexpressing H69AR cells for all tested concentrations. To determine if the 
difference observed between the two cell lines is specifically due to MRP1 transport 
activity, effect of MRP1 inhibitor, MK571, was observed at different doxorubicin 
incubation times. As shown in Fig. 1B, MRP1 inhibition by MK571 did not affect the 
doxorubicin accumulation in H69 cells irrespective of the doxorubicin incubation time. In 
contrast, MRP1-overexpressing H69AR cells showed much higher doxorubicin 
accumulation with MK571 treatment compared with untreated H69AR cells at all 
doxorubicin incubation time points (Fig. 2.1C). These data provide the basis and feasibility 
of using H69AR cells to develop a high-throughput screening assay to identify inhibitors 
of MRP1 using doxorubicin as a fluorescent substrate reporter. 
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Figure 2.1 Concentration- and time-dependent accumulation of doxorubicin in H69 and 
H69AR cells 
A. H69 and H69AR cells were treated with doxorubicin at various concentrations (1–30 
µM) for 1 h. Representative images of doxorubicin treatment at 1, 3, and 10 µM are shown. 
The average fluorescence intensities derived from the fluorescent images were graphed and 
shown on the right. B. H69 cells were treated with 10 µM doxorubicin in the absence and 
presence of 50 µM MK571 for 15–180 min. Representative images of doxorubicin 
treatment at 30, 60, and 90 min are shown. C. H69AR cells were treated with 10 µM 
doxorubicin in the absence and presence of 50 µM MK571 for 15–180 min. Representative 
images of doxorubicin treatment at 30, 60, and 90 min are shown. Data are representative 
of two experiments and shown as mean ± SD (n = 3). 
 
3.2 Screening of anti-cancer compound library for MRP1 inhibitors 
After the development and optimization of high-content imaging-based MRP1 efflux assay 
using doxorubicin, we sought to identify novel MRP1 inhibitors within a library of 386 
anti-cancer small molecules under clinical trials for 12 different types of cancers. The anti-
cancer library was screened using MRP1-overexpressing H69AR cells and doxorubicin as 
a fluorescent substrate reporter. Treatment with 50 µM MK571 (a commonly used MRP1 
inhibitor) was considered as 100% MRP1 inhibition for calculating percent inhibition for 
the test compounds. Three independent screening experiments were done using the 96-well 
format. The relative MRP1-inhibitory activities of the test compounds from three 
independent experiments are represented as a 3D scatter plot (Fig. 2.2). As indicated in 
Fig. 2.2 (bottom), the assay had good reproducibility with a correlation range of 0.73-0.85 
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between any two given experiments. The quality and performance of the assay was also 
assessed by deriving the Z’-factor from the experiments. The average Z’-factor across all 
plates was 0.58, indicating a good assay performance. A positive hit was defined as a 
compound with ≥ 40% mean percent inhibition. Using this threshold value, we identified 
a total of 33 hit compounds. Five of the hits were autofluorescent compounds and were 
discarded. The remaining 28 hit compounds are displayed as red dots in the 3D scatter plot 
(Fig. 2). Identified MRP1 hits, together with their therapeutic targets and percent inhibition 
are shown in Table 1. Ten of the 28 hits were recently identified by our group by screening 
the anti-cancer library using calcein as a fluorescent substrate and are listed in Table 1 as 
well. Among the remaining 18 hit compounds, celecoxib and LY294002 have been 
reported as MRP1 inhibitors [24, 25] while 16 anti-cancer hit compounds have not been 
previously reported to inhibit MRP1 transport activity. The structure of the 18 hit 
compounds is presented in Fig. 2.3. 
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Figure 2.2 Performance of the imaging-based MRP1-mediated doxorubicin accumulation 
screening assay 
Screening of the anti-cancer compound library was performed in three independent 
experiments at compound concentration of 10 µM. The relative inhibitory activities of each 
compound were calculated and displayed as a 3D plot. Red dots represent compounds with 
mean percent inhibition of ≥50%. The table below the plot shows correlation coefficients 
between any two experiments. 3D scatter plot was generated using SigmaPlot 12.0 and 
Correlation coefficient 
54 
 
correlation coefficients were calculated using MS Excel. Correlation and graph exclude 5 
compounds identified as autoflourescent.  
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Table 2.1 Chemotherapeutic targets, % inhibition for calcein/doxorubicin 
accumulation inhibition for identified MRP1 inhibitors 
Compound Chemotherapeutic 
targets 
% Doxorubicin 
Inhibition 
% Calcein 
Inhibition 
MK-571  100.0 ± 0 100.0 ± 0 
Tipifarnib  Transferase 86.3 ± 9.3 199.1 ± 56.8 
AZD1208 Pim 71.2 ± 13.8 145.7 ± 25.3 
Rapamycin  Autophagy 66.1 ± 10.0 142.5 ± 12.2 
Deforolimus  mTOR 74.6 ± 10.9 111.9 ± 19.4 
HS-173 PI3K 86.7 ± 7.7 94.0 ± 21.8 
YM201636 PI3K 54.3 ± 5.9 81.9 ± 4.9 
ESI-09   74.6 ± 11.8 
Everolimus  mTOR 69.2 ± 4.6 72.6 ± 7.8 
TAK-733 MEK 59.4 ± 8.9 67.4 ± 12.7 
CX-6258 Pim  57.1 ± 16.4 
Cyclosporin A  61.3 ± 11.6 50.2 ± 2.7 
Temsirolimus mTOR 45.0 ± 4.0 43.3 ± 4.2 
GSK2126458 mTOR 94.0 ± 13.5  
Flavopiridol  CDK 68.4 ± 7.1  
Mifepristone   67.5 ± 7.1  
NVP-BSK805  JAK 65.8 ± 0.8  
Saracatinib  Src 65.7 ± 3.4  
Alisertib Aurora A kinase 64.1 ± 10.3  
OSI-420 EGFR 57.8 ± 2.7  
LY294002 PI3K 56.6 ± 5.3  
Rosiglitazone   56.1 ± 3.6  
Alvespimycin HSP90 55.9 ± 7.4  
MK-2206  AKT 54.1 ± 16.0  
Celecoxib COX-2 53.4 ± 6.7  
Amuvatinib  C-Kit 53.3 ± 6.5  
LY2228820 P38 MAPK 53.3 ± 4.1  
GSK461364 PIK1 52.7 ± 1.3  
GW4064 FXR 52.3 ± 1.8  
Afatinib  EGFR 50.9 ± 7.7  
Doramapimod MAPK 50.8 ± 2.0  
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Figure 2.3 Chemical Structures of the selected 18 hit compounds. 
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3.3 Validation of identified MRP1 inhibitors  
To verify the inhibitory activities of the hit compounds obtained from the initial high-
content screening and to identify any false hits, we performed doxorubicin accumulation 
assay using two different traditional and well-established methods. First, we used confocal 
microscopy to visualize the inhibitory effects of the hit compounds on MRP1-mediated 
doxorubicin efflux. For this assay, HEK293T cells were transiently transfected with a 
vector encoding recombinant MRP1-GFP protein. The beauty of this experiment is that 
transient transfection allows mixed population of cells with and without MRP1-GFP and 
creates negative control within the system to easily visualize MRP1-dependent doxorubicin 
efflux side by side in the same image. As shown in Fig. 2.4A, no drug treatment control 
cells showed high doxorubicin accumulation in the nuclei of non-transfected cells, while 
doxorubicin fluorescence was very low or undetectable in cells expressing MRP1-GFP. 
MRP1-mediated efflux of doxorubicin was blocked by MK-571 (50 µM), which was used 
as the positive control. All the test compound (10 µM) treatments increased doxorubicin 
accumulation in MRP1-GFP expressing cells to a certain extent reflecting inhibition of 
doxorubicin efflux by MRP1. Treatment with NVP-BSK805 showed the weakest response. 
Next, we also performed more quantitative doxorubicin accumulation assay using flow 
cytometry method. In this assay, MRP1-overexpressing H69AR stable cells were pre-
treated with the test compounds for 1 hour before treatment with doxorubicin for another 
2 hours. As shown in Figure 4B, MK-571 at 50 µM enhanced doxorubicin accumulation 
in H69AR cells by 2-fold compared to no treatment control. All the tested hit compounds 
(10 µM) exhibited increased doxorubicin accumulation in H69AR cells to varying levels 
(~1.5 to 2.7-fold). Based on both confocal and flow cytometry assays, hit compounds 
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GSK2126458, doramapimod, MK2206, mifepristone and celecoxib showed strong 
inhibition of doxorubicin efflux by MRP1 while the remaining compounds showed 
moderate to weak inhibition. 
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Figure 2.4 Validation of MRP1-inhibitory activity of identified hit compounds 
A. HEK293T cells transiently transfected with MRP1-GFP (green) were pre-treated with 
10 µM test compounds for 30 min, before treatment with doxorubicin (red) at 37 °C for 1 
h. Images were acquired using confocal microscopy. GFP and doxorubicin were excited at 
488 nm, and detected at 475/42 and 605/64 nm, respectively. B. H69AR cells were pre-
treated with 50 µM MK571 or 10 µM test compounds for 1 h before treatment with 10 µM 
doxorubicin at 37 °C for 2 h.  Fluorescence intensities of intracellular doxorubicin were 
detected using flow cytometry, with excitation and emission wavelengths of 488 and 
610/20 nm, respectively. Data are combined from two experiments and presented as mean 
± SEM.  *, p value lower than 0.05 compared with control. 
 
3.4 Membrane Transport assay for MRP1 inhibitors 
Since MRP1 plays a very important physiological role in detoxification and tissue defense. 
We were interested in evaluating the effects of the hit compounds on MRP1-mediated 
transport of endogenous organic anions. For this purpose, we employed membrane-based 
vesicular uptake assay for E217βG, a glucuronide conjugate and a prototypical 
physiological substrate of MRP1. HEK293/pcDNA 3.1 and HEK293/MRP1 cells were 
used to prepare membrane vesicles. MRP1 transport activity was measured using 
[3H]E217βG  as substrate and hit compound treatments were done at 10 µM. As shown in 
Fig. 2.5, ATP-dependent uptake of [3H]E217βG into HEK293/pcDNA3.1 (vector control) 
membrane vesicles was less than 1% of uptake by HEK293/MRP1 membrane vesicles. 
Uptake of [3H]E217βG into HEK293/MRP1 membrane vesicles was reduced by ~95% with 
10 µM MK571. Among the hit compounds, alisertib, GSK461364 and GW4064 exhibited 
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strong MRP1 inhibition and reduced the uptake of [3H]E217βG by 66%, 67% and 70% 
respectively. In contrast, afatinib, celecoxib, doramapimod, flavopiridol, LY294002, MK-
2206, OSI-420, rosiglitazone and saracatinib showed no inhibition or modest inhibition of 
[3H]E217βG uptake into HEK293/MRP1 membrane vesicles.  
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Figure 2.5 Effects of test compounds on [3H]E217βG uptake into MRP1 expressing 
membrane vesicles.  
Membrane vesicles were prepared from stable HEK293/pcDNA3.1 and HEK293/MRP1 
cells. Membrane vesicles (2 µg protein) were incubated with 10 µM test compounds. 
Reactions were performed using 400 nM/20 nCi [3H] E217βG at 37 °C for 1 min. 
Radioactivity retained on collected membrane vesicles was quantified using liquid 
scintillation counting. Data are combined from two experiments and presented as mean ± 
SEM, * p value lower than 0.05 compared with control. 
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3.5 Resistance reversal by selected MRP1 inhibitors 
Development of MDR is the biggest hurdle in the success of chemotherapy. We were 
interested to determine if the identified anti-cancer hit compounds can reverse drug 
resistance in a MRP1-overexpressing MDR cell line. MDR reversal ability of a drug may 
be valuable in combinatorial therapies of malignancies where MRP1 is overexpressed. In 
addition, drugs which show substrate selectivity and can inhibit the efflux of cancer drugs 
without significantly interfering with the efflux of physiological organic anions by MRP1 
may have a better chance of success in chemotherapy. We selected 6 compounds (afatinib, 
celecoxib, doramapimod, mifepristone, MK-2206 and rosiglitazone) from the total 18 hit 
compounds to conduct resistance reversal experiments based on the available data. The 
abilities of the selected compounds were evaluated to reverse resistance of MRP1-
overexpressing H69AR lung cancer cells against vincristine, doxorubicin and etoposide. 
These cytotoxic anti-cancer agents are very commonly used in chemotherapy and are well-
established substrates of MRP1. First, concentration response was conducted for selected 
drug hits to evaluate the cytotoxicity profile of these compounds in H69AR (data not 
shown). Selected hit compounds at non-cytotoxic concentrations were then administered 
in combination with increasing concentrations of vincristine, doxorubicin or etoposide to 
determine the resistance level of H69AR cells. As shown in Fig. 6, MRP1-overexpressing 
H69AR cells (solid red) showed MDR and as expected exhibited much lower sensitivity 
towards each of the three cytotoxic cancer drugs than H69 cells (dotted red). IC50 values 
and fold resistance of the parental H69 and the MRP1-overexpressing derivative H69AR 
cells treated with vincristine, doxorubicin or etoposide with or without the selected 
compounds are presented in Table 2.2. 
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In case of vincristine, H69AR cells were 35-fold more resistant than the parental H69 cells 
and MRP1 inhibitor MK571 (10 µM) reduced the fold resistance of H69AR cells to 14-
fold. Among the selected 6 hit compounds, mifepristone and doramapimod were most 
effective in sensitizing H69AR cells against vincristine and reduced the fold resistance to 
3 and 6-fold respectively. The remaining hit compounds showed comparable reversal as 
standard MRP1 inhibitor MK571. H69AR cells were 23-fold more resistant towards 
doxorubicin compared with H69 cells. Mifepristone and rosiglitazone proved most 
effective in sensitizing H69AR cells against doxorubicin and reduced the fold resistance to 
2.6 and 3.1-fold respectively. Afatinib, alisertib, celecoxib and doramapimod showed 
similar resistance reversal as MK571. In the absence of any inhibitor, H69AR cells also 
exhibited 5.6-fold more resistance towards etoposide compared with H69 cells. 
Doramapimod, celecoxib and alisertib were able to completely reverse resistance of 
H69AR cells against etoposide. In contrast, presence of afatinib failed to show any 
reduction in the resistance level against etoposide. Hit compounds mifepristone, MK-2206 
and rosiglitazone showed only moderate levels of reduction in resistance of H69AR cells 
against etoposide. 
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Figure 2.6 Reversal of drug resistance towards vincristine, doxorubicin and etoposide in 
H69AR cells by selected MRP1 inhibitors. 
A. H69 and H69AR cells were treated with vincristine at increasing concentrations in the 
absence and/or presence of selected MRP1 inhibitors. B. H69 and H69AR cells were 
treated with doxorubicin at increasing concentrations in the absence and/or presence of 
selected MRP1bitors C. H69 and H69AR cells were treated with etoposide at increasing 
concentrations in the absence and/or presence of selected MRP1 inhibitors. A, B and C. 
MK571, doramapimod, mifepristone, and rosiglitazone were at 10 µM, MK-2206 and 
celecoxib were at 2 µM, afatinib was at 1 µM. Cell viability was evaluated with MTT after 
72 h. Data are representative of three experiments and presented as mean ± SD (n = 3).  
Table 2.2 The effects of selected MRP1 inhibitors on the IC50 values of vincristine, 
doxorubicin and etoposide in H69 and H69AR cells 
Cell line/Treatment Vincristine Doxorubicin Etoposide 
 
IC50 a (nM) Fold 
resistance b 
IC50 a (µM) Fold 
resistance b 
IC50 a (µM) Fold resistance b 
  
H69 0.67 ± 0.08  1.00 0.14 ± 0.05  1.00 4.43 ± 1.97  1.00 
H69AR  23.35 ± 0.34 34.69 3.31 ± 0.32 22.93 24.68 ± 2.23 5.57 
H69AR + MK571 10 µM 9.33 ± 1.43  13.86 1.05 ± 0.04  7.25 7.97 ± 1.10  1.80 
H69AR + Afatinib 1 µM 14.68 ± 1.57  21.80 1.16 ± 0.21  8.05 28.34 ± 1.03 6.40 
H69AR + Celecoxib 2 µM 10.54 ± 0.19 15.66 1.19 ± 0.15  8.28 4.78 ± 0.35  1.08 
H69AR + Doramapimod 10 
µM 
4.08 ± 0.06  6.06 1.21 ± 0.25  8.39 4.18 ± 0.52  0.94 
H69AR + Mifepristone 10 
µM 
2.13 ± 0.40  3.16 0.38 ± 0.10  2.65 11.58 ± 1.99  2.62 
H69AR + MK-2206  2 µM 15.40 ± 2.5  22.87 2.09 ± 0.05  14.50 14.54 ± 1.89 3.28 
H69AR + Rosiglitazone 10 
µM 
14.85 ± 1.13  22.20 0.44 ± 0.05  3.07 13.14 ± 0.03  2.97 
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aMean ± SEM of n ≥ 3 independent experiments.  
bFold resistance is the ratio between IC50 value of each treatment and IC50 value of 
vincristine, doxorubicin and etoposide alone in H69 cells. 
 
3.6 Effects of selected hit compounds on drug sensitivity of HEK293/BCRP and 
HEK293/P-gp cells 
Among ABC drug transporters, P-gp, MRP1 and BCRP  are most frequently implicated in 
MDR. Therefore, we were interested in investigating the potential of selected MRP1 
inhibitors to reverse drug resistance of P-gp and BCRP-overexpressing cell lines. 
HEK293/BCRP and HEK293/P-gp cells were treated with increasing concentrations of 
mitoxantrone and vincristine, respectively, in the presence and absence of selected hit 
compounds. Ko143 and verapamil were used as known inhibitors of BCRP and P-gp, 
respectively. As shown in Fig. 7, BCRP and P-gp-overexpressing cells (solid red) exhibited 
much lower sensitivity towards mitoxantrone and vincristine, respectively, than the vector 
control cell line HEK293/pcDNA3.1 (dotted red). Treatment of HEK293/BCRP and 
HEK293/P-gp cells with Ko143 and verapamil, respectively, reversed the resistance of the 
cells. IC50 values and fold resistance are presented in Table 3. Doramapimod and 
mifepristone were able to completely reverse the resistance of HEK293/BCRP cells against 
mitoxantrone while the remaining selected hits showed only modest to moderate reversal. 
In case of HEK293/P-gp cells, mifepristone treatment completely reversed the resistance 
against vincristine while doramapimod exhibited modest resistance reversal. In contrast, 
treatment with afatinib or celecoxib led to increased resistance of HEK293/P-gp cells 
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against vincristine. Alisertib, MK-2206 and rosiglitazone did not significantly reduce the 
resistance levels of HEK293/P-gp cells. 
 
Figure 2.7 Effects of selected MRP1 inhibitors on drug sensitivity of HEK293/BCRP and 
HEK293/P-gp cells. HEK293/BCRP  
(A) and HEK293/P-gp (B) were treated with increasing concentrations of mitoxantrone 
and vincristine, respectively in the absence and /or presence of selected MRP1 inhibitors. 
Afatinib was at 1µM, celecoxib and MK-2206 were at 2 µM while doramapimod, 
mifepristone and rosiglitazone were at 10 µM. Ko143 (1 µM) and verapamil (25 µM) were 
used as positive controls in HEK293/BCRP and HEK293/P-gp cells, respectively. 
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HEK293/pcDNA cells were included as negative control for drug resistance. Cell viability 
was evaluated with MTT after 72 h. Data are representative of three experiments and 
presented as mean ± SD (n = 3). 
Table 2.3 Effect of selected MRP1 inhibitors on IC50 of mitoxantrone and vincristine 
and in HEK293/BCRP and, HEK293/P-gp respectively 
Cell line/Treatment Mitoxantrone Vincristine 
 IC50 a (nM) Fold 
resistance b 
IC50a (µM) Fold 
resistance b 
HEK293/pcDNA3.1 4.57 ± 1.48 1   
HEK293/BCRP (control) 28.36 ± 4.1 6.21   
HEK293/BCRP + Ko143 1µM 1.33 ± 0.14 0.29   
HEK293/BCRP + Afatinib 1µM 17.37 ± 1.58 3.80   
HEK293/BCRP + Celecoxib 2 µM 19.91 ± 3.68 4.36   
HEK293/BCRP + Doramapimod 10 µM 2.52 ± 0.22 0.55   
HEK293/BCRP + Mifepristone 10 µM 4.40 ± 0.33 0.96   
HEK293/BCRP + MK-2206 2 µM 22.5 ± 1.85 4.93   
HEK293/BCRP + Rosiglitazone 10 µM 20.04 ± 4.68 4.39   
     
HEK293/pcDNA3.1   0.0037 ± 0.0013 1 
HEK293/P-gp (control)   1.40 ± 0.17 376.86 
HEK293/ P-gp + Verapamil 25 µM   0.0030 ± 0.0012 0.80 
HEK293/ P-gp + Afatinib 1 µM   2.92 ± 0.09 788.73 
HEK293/ P-gp + Celecoxib 2 µM   3.83 ± 0.46 1034.51 
HEK293/ P-gp + Doramapimod 10 µM   0.12 ± 0.07 31.23 
HEK293/ P-gp + Mifepristone 10 µM   0.0032 ± 0.0002 0.88 
HEK293/ P-gp + MK-2206 2 µM   0.81 ± 0.46 218.64 
HEK293/ P-gp + Rosiglitazone 10 µM   0.58 ± 0.07 157.86 
a Mean ± SEM of n ≥ 3 independent experiments  
bFold resistance is the ratio between IC50 value of each treatment and IC50 value of 
mitoxantrone or vincristine alone in the parental cell line HEK293/pcDNA3.1.  
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4.0 Discussion 
MDR is a major problem in the treatment of malignancies as it increases the effective dose 
of anticancer agents to more lethal levels. The capacity of MRP1 to efflux drugs prevents 
the effective treatment of cancers when overexpressed. MRP1 although localizes primarily 
at the plasma membrane of the cells, has also been found in the membranes of sub-cellular 
organelles such as mitochondria, endoplasmic reticulum and endocytic vesicles [26]. The 
localization of MRP1 in sub-cellular organelles has been hypothesized to serve as a 
sequestering mechanism to prevent drugs from reaching their respective intracellular 
targets [3, 27]. MRP1 is known to be overexpressed in cancers such as neuroblastoma [28], 
acute lymphoblastic leukemia [29], breast [30], tongue [31], brain [32], small-cell lung 
carcinoma [33] and prostate [34]. It has also been linked with survival of patients with 
ovarian [35], neuroblastoma [36] and acute leukemia [37]. MRP1-overexpression has been 
implicated with MDR in lung, breast, prostate cancers and different types of leukemia. 
Inhibition of MRP1-mediated transport by small molecules to resensitize drug resistant 
cells provides the possibility of overcoming MDR in malignancies where MRP1 is 
overexpressed and linked to patient survival. 
Chemotherapy is the most common type of treatment for various types of cancers. 
Conventional cytotoxic anticancer drugs such as vincristine, doxorubicin, cisplatin, 
paclitaxel, and methotrexate are still commonly used in cancer chemotherapy. Because 
these agents target essential and fundamental cellular processes, they are very cytotoxic 
and not cancer specific. Major problems limiting the success of chemotherapy are MDR, 
tumor cell heterogeneity and toxicity. To address MDR and tumor heterogeneity, 
combination cancer therapy is frequently used, where drugs from different families 
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targeting different cellular mechanisms are combined to achieve better outcomes. To 
address the toxicity issue associated with chemotherapy, the focus in cancer therapeutics 
is to identify drugs that show high selectivity towards cancer cells and target specific cell 
signaling pathways. Many new compounds have been discovered that target specific 
enzymes, kinases, and receptors, and are being tested in clinical trials for better efficacy 
and reduced toxicity. Given the remarkable ability of MRP1 to significantly alter the 
bioavailability of a broad spectrum of drugs and the fact that MRP1-overexpression has 
been implicated in MDR of different types of cancer, it is very important to profile any 
new anticancer drug candidates for their interaction with this transporter. For successful 
cancer treatment, especially in cancers where MRP1-overexpression is associated with 
poor clinical outcome, it will be desirable to either inhibit MRP1 activity or use drugs that 
are not substrates of MRP1. In this study we investigated the interaction of MRP1 with a 
unique library of anti-cancer compounds which are being clinically tested as targeted 
cancer drugs. We are especially interested to identify inhibitors of MRP1 from this library 
because such compounds can act as dual-edge sword. In addition to working as a targeted 
cancer drug, it can also reverse MRP1-mediated drug resistance or can be used to improve 
the efficacy and reduce the toxicity of MRP1 substrate drugs.  
In the present study, we have successfully developed and validated a high content imaging-
based efflux assay for MRP1 transport activity using doxorubicin as a fluorescent reporter 
substrate. To the best of our knowledge, doxorubicin has never been successfully used as 
a substrate in a high content screening or any other high-throughput screening assay to 
identify inhibitors of MRP1 activity. Screening a unique library of 386 anti-cancer 
compounds currently under clinical trials targeting 12 types of cancers, we identified a total 
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of 28 MRP1 inhibitors. The assay exhibited high correlation (0.73−0.85) among the three 
independent screening experiments. The high quality and performance of this screening 
assay was demonstrated by Z’-factor of 0.58 across all plates. The high-through screening 
assay developed in this study has several advantages over assays that measure fluorescence 
intensity using microplate reader or flow cytometry. This high-content screening method 
uses automated imaging and offers very advance and sophisticated image analysis tools to 
remove the non-specific and background fluorescence leading to a very robust and precise 
assay with high dynamic range between the positive and negative controls. In addition, this 
live cell-based assay allows simultaneous detection of cell permeable, non-toxic and potent 
inhibitors. There is convincing biochemical and structural data to suggest that MRP1 has 
multiple distinct substrate binding sites. However, only calcein-AM as a substrate has been 
used in cell-based assays for MRP1 inhibition screening. The doxorubicin-based new assay 
developed was able to identify 10 of 12  hits previously identified using calcein-based 
screening and in addition discovered many new drugs as inhibitors of MRP1. These 
findings suggest that doxorubicin binding site overlaps with calcein binding site and may 
have an additional binding site. Furthermore, the new assay signifies the importance of 
MRP1 for drug discovery and development. 
Among the 28 hit compounds identified as MRP1 inhibitors in the doxorubicin-based 
screening of anticancer compounds, 10 compounds (tipifarnib, AZD1208, rapamycin, 
deforolimus, HS-173, YM201636, everolimus, TAK-733, cyclosporin A, and 
temsirolimus) were recently identified by our group using calcein-based screening assay. 
Therefore, we focused on the characterization of the remaining 18 MRP1 inhibitors. Two 
of the novel inhibitors identified in this study, namely alisertib and amuvatinib, are being 
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actively investigated for their anticancer efficacy and have never been reported to interact 
with any ABC drug transporter. Alisertib, a second-generation aurora kinase A and B 
inhibitor with a higher affinity for aurora kinase A is identified for the first time to interact 
with MRP1. Alisertib showed strong inhibition of MRP1-mediated transport of 
doxorubicin and E217βG (Fig. 3 and 4). P-gp and BCRP expression have been reported to 
decrease the anti-cancer activity of pan-aurora kinase inhibitor tozasertib but not of the 
aurora kinase inhibitor alisertib indicating that alisertib is not a substrate of these ABC 
transporters [38, 39]. Two compounds, celecoxib and LY294002, have been previously 
shown to inhibit MRP1 efflux function [24, 25] while anti-cancer drugs mifepristone and 
rosiglitazone although have not been reported to be a substrate or inhibitor of MRP1 
directly but have been shown to reverse resistance of cells overexpressing P-gp and MRP1 
[40, 41]. 
Eleven of the 18 hit drugs have been reported previously to be a substrate or inhibitor of 
P-gp or BCRP but not have been reported to interact with MRP1. GW4064 has been 
reported to induce the MRP2 mRNA levels [42] while MK2206 was reported to decrease 
P-gp expression [43] but neither of these drugs has been reported as substrate or inhibitor 
of P-gp, BCRP or MRP1. In addition to cell-based assays that measured doxorubicin efflux 
inhibition, we also employed membrane-based vesicular uptake assay to evaluate the 
effects of hit compounds on MRP1-mediated transport of endogenous organic anion, 
E217βG, a prototypical physiological substrate of MRP1. Ten of the 18 compounds 
(LY294002, OSI-420, rosiglitazone, MK-2206, flavopiridol, doramapimod, afatinib, 
celecoxib, alvespimycin and amuvatinib) showed no or weak inhibition of MRP1-mediated 
E217βG transport. Substrate selective inhibition of MRP1 may be very critical in the 
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potential application of these anti-cancer agents in reversing MDR. An anti-cancer agent 
that blocks the efflux of therapeutic drug without interfering with the efflux of important 
physiological substrates may exhibit less toxic side effects.  
Six of the hit compounds were evaluated to reverse resistance of MRP1-overexpressing 
H69AR lung cancer cells against vincristine, doxorubicin and etoposide. Mifepristone, 
doramapimod and celecoxib were most effective in reversal of MRP1-mediated drug 
resistance. Mifepristone is a progesterone and glucocorticoid hormone antagonist and has 
been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. 
Mifepristone has been reported to reverse drug resistance in cells overexpressing P-gp as 
well as in SGC790/VCR cell line overexpressing both P-gp and MRP1. In this study, 
mifepristone was able to sensitize MRP1-overexpressing H69AR cells against vincristine 
(reduced IC50 from 23.35 to 2.13 nM), doxorubicin (reduced IC50 from 3.3 to 0.38 nM), and 
etoposide (reduced IC50 from 24.68 to 11.58 µM). We report that mifepristone is a MRP1, 
P-gp and BCRP pan inhibitor since it was able to completely reverse resistance of P-gp and 
BCRP-overexpressing cells against vincristine and mitoxantrone, respectively. As of June 
16th, 2019, there are currently 146 clinical trials registered (clinicaltrials.gov) and many of 
them are focused on evaluating the anti-cancer potential of mifepristone for various types 
of cancers. Doramapimod is a p38 MAPK inhibitor and has been reported to enhance 
cytotoxicity of anticancer drugs in P-gp overexpressing cell lines [44]. We are the first to 
report its interaction with MRP1. In this study, doramapimod was able to sensitize MRP1-
overexpressing H69AR cells against vincristine (reduced IC50 from 23.35 to 4.08 nM), 
doxorubicin (reduced IC50 from 3.3 to 1.21 nM), and etoposide (reduced IC50 from 24.68 
to 4.18 µM). Here we report that doramapimod is a MRP1, BCRP and P-gp pan inhibitor 
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since it was able to completely reverse resistance of BCRP-overexpressing cells against 
mitoxantrone and exhibited strong resistance reversal of P-gp overexpressing cells against 
vincristine. Celecoxib is a selective cyclooxygenase inhibitor. In this study, celecoxib was 
able to completely reverse the resistance of MRP1-overexpressing H69AR cells against 
etoposide whereas only modest drug reversal was observed against vincristine and 
doxorubicin reflecting substrate selective inhibition. In contrast, we observed that 
celecoxib enhanced the cytotoxicity of vincristine in HEK-P-gp overexpressing cells. In 
addition, we report that celecoxib was ineffective in reversing resistance of HEK-BCRP 
overexpressing cells against mitoxantrone. Interestingly, a gene array analysis 
investigating the expression of all 48 human ABC transporters found ABCC1 and ABCC6 
to be highly expressed in the MCF7VP breast cancer cell line (etoposide-resistant cell line) 
compared to the MCF7 (parental sensitive cell line) whereas the expression of other 
transporters was not appreciably increased [45]. This report is consistent with our findings 
and highlights the role of MRP1 in resistance against etoposide. 
In summary, we demonstrated the effectiveness and value of a novel doxorubicin-based 
high content imaging-based assay to study compound interaction with MRP1. This study 
identified 16 anti-cancer agents as MRP1 inhibitors which have not been previously 
reported as a substrate or inhibitor of MRP1. The anti-cancer drugs which did not exhibit 
interaction with MRP1 may have a lower risk of being interfered by MRP1-mediated 
MDR.  
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CRO-9 screening of unique anticancer library identifies novel inhibitors of human 
MRP1 (ABCC1). 
 
Abstract 
Multidrug resistance protein 1 (MRP1/ABCC1) transports a variety of drugs, toxic 
molecules and important physiological substrates across the plasma membrane and 
physiological barriers. MRP1 plays an active role in protecting cells by effluxing a vast 
array of drugs to sub-lethal levels. Additionally, its overexpression has been implicated in 
multidrug resistance in various cancers. We recently reported development of a high 
content efflux assay using doxorubicin as fluorescent reporter which identified MRP1 
inhibitors missed by calcein-AM in a similar assay. Here, we describe the development of 
a new high content imaging-based efflux assay using CRO-9 as a fluorescent reporter. 
Taking advantage of multiple binding sites of MRP1, we screened the same anti-cancer 
library of 386 compounds using CRO-9. The new assay identified a total of 50 MRP1 
inhibitors including 19 inhibitors that have not been previously reported as inhibitors of 
MRP1. The inhibitory activity of compounds was confirmed using flow cytometry 
confocal microscopy, and membrane vesicle-based transport assays. Six drugs 
(GSK650394, KU-0063794, LY2603618, MK0752, NU7441 and ZSTK474) were 
evaluated for their ability to reverse resistance of MRP1-overexpressing H69AR lung 
cancer cells against vincristine, and SN38. LY2603618 and ZSTK474 were the most 
effective in reversing resistance of H69AR cells against vincristine and SN38. NU7441 
was more effective in reversing resistance against SN38 as compared to resistance of 
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H69AR to vincristine. Our findings indicate the importance of MRP1 in drug discovery 
and demonstrate the advantage of CRO-9 as a fluorescent reporter in a high content 
screening assay. Anti-cancer agents that exhibit MRP1 inhibition and ability to reverse 
resistance may be used in combination therapy to improve the efficacy and reduce the 
toxicity of other cancer chemotherapies.  
 
Keywords: MRP1; ABCC1; ABC transporter; multidrug resistance; MRP1 inhibitors; high 
content screening; anti-cancer agent; drug-transporter interactions; CRO-9; drug profiling 
 
Chemical compounds studied in this article: 
1) AUY922 (PubChem CID: 135539077); 2) BIBR 1532 (PubChem CID: 9927531); 3) 
Bosutinib (PubChem CID: 5328940); 4) CT99021(9956119); 5) CW069 (PubChem CID: 
73427517); 6) Evista (PubChem CID: 59400); 7) Gefitinib (PubChem CID: 123631); 8) 
GSK1120212 (PubChem CID: 11707110); 9) GSK650394 (PubChem CID: 5022668); 10) 
Ibrutinib (PubChem CID: 24821094); 11) Ku-0063794 (PubChem CID: 16736978); 12) 
Ku-55933 (PubChem CID:5278369); 13) Ly2603618 (PubChem CID: 11955855); 14) 
Mk-0752 (PubChem CID: 9803433); 15) Nu7441(PubChem CID:11327430); 16) Nutlin 
3(PubChem CID: 11433190); 17) Nutlin 3a (PubChem CID: 216345); 18) 
Pf562271(PubChem CID: 11713159); 19) PIK75 (PubChem CID: 9825070); 20) Ponatinib 
(PubChem CID: 24826799); 21) WIKI4 (PubChem CID: 2984337); 22)Wp1130 
(PubChem CID: 11222830); 23) ZSTK474 (PubChem CID: 11647372) 
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1.0 Introduction 
One of the challenges to effective cancer treatment is multidrug resistance which decreases 
long term survival rate of patients despite advances in cancer therapy [1]. Multidrug 
resistance (MDR) is the phenomenon where cancer cells become resistant and 
unresponsive to a variety of chemotherapeutic agents. Mechanisms of MDR in cancer 
includes activation of DNA repair mechanism, interference in apoptotic signaling 
pathways, activation of drug metabolizing enzymes and overexpression of drug 
transporters [2]. The overexpression of drug transporters is the most common mechanism 
of MDR and is widely studied [3]. Underlying this type of MDR is active efflux of variety 
of structurally and functionally unrelated pharmacological agents from cells. The 
superfamily of drug transporters called ATP binding cassette (ABC) transporters have been 
implicated to confer resistance to clinically active drugs especially P-glycoprotein (P-
gp/ABCB1), breast cancer resistant protein (BCRP, ABCG2) and multidrug resistant 
protein 1 (MRP1/ ABCC1)[4, 5]. These drug transporters actively pump out 
chemotherapeutic drugs reducing the intracellular levels of drugs and consequently drug 
efficacy. These transporters are also impediments in the treatments of neurological 
disorders , epilepsy as they are present at the brain blood barrier and extrude xenobiotics 
from the CNS[6]. The expression of MRP1 in peripheral blood mononuclear cells of 
children who have intractable epilepsy is increased as compared to children with epilepsy 
controlled by anti-epileptic drugs (AED) and normal children [7]. 
The ABC transporters are classified into seven subfamilies (A through G) based on their 
sequence homology [8]. The mammalian ABC transporters are made up of four domains 
often encoded as a single polypeptide (e.g. P-gp) but are sometimes two polypeptides that 
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form homodimers (e.g. ABCG2) or heterodimers (e.g. TAP1/TAP2) [9]. MRP1 and several 
ABCC homologs have a five-domain structure with two nucleotide binding domains 
(NBDs) and 17 transmembranes in three membrane spanning domains (MSD0, MSD1, and 
MDS2) [10].  
The NBDs each contain three key motifs i.e. Walker A and B motifs characteristic of P-
loop ATPases and an “active transport” signature motif common to all ABC proteins [9]. 
Transport by MRP1 (and other ABC transporters) is driven by the binding and hydrolysis 
of ATP, which promotes the required protein conformation changes that aids solute 
translocation. The two NBDs form a “sandwich” dimer, with two ATP molecules 
sandwiched in the dimer interface. In the ‘sandwich dimer’ the two ATP-binding sites 
comprise of the Walker motifs of one NBD and the active transport signature motif of the 
other [9]. The ATP-binding sites of MRP1 are functionally nonequivalent. NBD1 has a 
higher affinity for ATP (but very low ATPase activity) whiles NBD2 has a greater capacity 
for ATP hydrolysis. MRP1 also has composite substrate-binding sites which permits both 
cooperativity and competition between various substrates [11]. 
MRP1 ( ABCC1) was first reported by Cole and colleagues  to mediate resistance  to 
doxorubicin, etoposide and vincristine [5]. MRP1 is ubiquitously expressed in normal 
tissues with elevated expression in kidney, lungs, thymus, cardiomyocytes and placenta 
with lower expression in colon, brain, small intestine and peripheral blood mononuclear 
cells [11,12]. The expression level of MRP1 can still vary between different cell types in 
the same tissue. The activity of MRP1 unlike P-gp is not limited to the efflux of xenobiotics 
but also endobiotics and other physiological substrates. As such it influences physiological 
processes such as transport of inflammatory mediators (extrusion of leukotriene) and 
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defense against oxidative stress (transport of glutathione and glutathione conjugates). 
Additionally, substrates of MRP1 and P-gp differ by their chemical properties. MRP1 
mostly transports organic anions, many of which are conjugated with glutathione (GSH, g-
Glu-Cys-Gly), glucuronic acid, or sulfate whereas P-gp recognizes unconjugated 
hydrophobic substrates [13]. 
Due to its protective roles, MRP1 expression is also elevated in cells with specialized 
barrier functions including choroid cells and capillary endothelial cells. MRP1 is located 
on the basolateral membrane of these polarized cells. MRP1 expression is elevated in 
rapidly proliferative cells such as reactive type II pneumocytes in lungs; and physiological 
barriers such as brain blood barrier(BBB) [14], blood testes [15], blood placental [16]. The 
overexpression of MRP1 in cancer cells can affect pharmacokinetic parameters of drug 
absorption, distribution, metabolism, excretion and toxicity (ADMET) [17]. Elevated 
levels of MRP1 confers resistance to various natural products and anticancer drugs such as 
vinca alkaloids, anthracyclines, epipodophyllotoxins [4].  
Not much is known about modulators of MRP1 at clinical trials. Although P-gp has been 
studied well, no P-gp modulator has been successful at clinical trials. This is mainly 
attributed to toxicity related issues and the fact that patients are not selected based on tumor 
expression of P-pg. To fully understand and determine the impact of ABC transporters on 
multidrug resistance in clinical trials, subpopulation of patients with ABC transporters as 
the main mechanism of multidrug resistance should be used. Identification of modulators 
of MRP1 and understanding fully the physiological and pharmacological consequences of 
doing so is of great interest due to its potential benefits in the treatment of drug resistant 
malignancies. 
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Previously, we developed, optimized and validated a high content imaging-based efflux 
assay to profile drug interactions with MRP1 [18] using calcein-AM. This assay was more 
robust and efficient as opposed to more traditional assays such as flow cytometry. This 
assay identified 12 novel MRP1 inhibitors after screening of a 384 unique anticancer 
library. Furthermore, the adaptation of this assay using doxorubicin as a fluorescent probe 
identified 28 inhibitors which included 10 of 12 inhibitors discovered previously with 
calcein-AM assay as well as 18 MRP1 inhibitors that were missed by the calcein-based 
screening [19]. The rationale for using doxorubicin was to take advantage of the wide range 
of the probe and multiple substrate nature of MRP1. Based on the promiscuity of MRP1 
substrate binding sites, we tested the hypothesis that using CRO-9 as a fluorescent reporter 
substrate, which is different in size and shape from doxorubicin and calcein-AM may 
identify new inhibitors. The screening of a 386  anticancer library with CRO-9 identified a 
total of 50 MRP1 inhibitors including 19 inhibitors that have not been previously reported 
as inhibitors. The remaining 31 inhibitors included 10 out of 12 compounds identified with 
calcein-AM and 17 out of 18 compounds exclusive to doxorubicin- based screening of the 
same library .We verified the inhibitory activity of the identified compounds exclusive to 
CRO-9 using flow cytometry and vesicular transport assays. The ability of some selected 
compounds to reverse the resistance of an MRP1-overexpressing MDR cancer cell line is 
also demonstrated.  
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2.0 Materials and methods 
2.1 Chemicals  
CRO-9, doxorubicin, adenosine monophosphate (AMP), adenosine triphosphate (ATP), 
estradiol 17-(β-D-Glucuronide) (E217βG), poly-D-lysine, thiazolyl blue tetrazolium 
bromide (MTT) were procured from Sigma-Aldrich (St. Louis, MO). MK571 was acquired 
from Cayman Chemical(Ann  Arbor,  MI) and [6,7-3H]E217βG (49.9 Ci mmol–1) from 
PerkinElmer (Waltham, MA). Anti-cancer compound library consisting of 386 anti-cancer 
small molecules under clinical trials for 12 different types of cancers was acquired from 
Selleck Chemicals (Houston, TX) 
 
2.2 Cell lines and cell culture 
H69 and H69AR cells were purchased from ATCC (Manassas, VA). HEK293T cells were 
provided by Dr. Adam Hoppe (South Dakota State University, Brookings, SD). HEK293 
and H69 cell lines were cultured in DMEM (GE Healthcare, Marlborough, MA) and RPMI 
1640 (ATCC), respectively, supplemented with 10% fetal bovine serum. Cells were grown 
in a humidified incubator maintaining 5% CO2 at 37°C. H69AR cells were exposed to 0.8 
µM doxorubicin monthly and cultured drug-free for a week before use. 
 
2.3 Screening for MRP1 inhibition via automated image acquisition and analysis 
The assay was developed and optimized using H69 and doxorubicin resistant cell line 
H69AR. CRO-9 was used as the fluorescent substrate and MK571 as the positive control. 
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Both cell lines were seeded at 6 × 104 cells per well in 100 µL culture medium in 96-well 
optical-bottom plates with polymer base (ThermoFisher Scientific, Waltham, MA) coated 
with poly-D-lysine (Sigma-Aldrich, St. Louis, MO) and allowed to attach overnight. 
Culture medium was replaced with 80 µL of serum-free medium. Prior to incubation with 
CRO-9, 10 µL of test compounds (10 µM final concentration), DMSO (0.2% final 
concentration) as negative control, or MK-571 (50 µM final concentration) as positive 
control were added and incubated for 30 min. A total of 10 µL of CRO-9 (0.25 µM final 
concentration) was added and incubated for an additional 30 min. Treatment was removed 
and 100 µL of PBS containing 10mM HEPES and 4.5% glucose was added post incubation.  
Images were obtained using an ImageXpress Micro XLS Widefield High-Content Analysis 
System (Molecular Devices, Sunnyvale, CA) equipped with a 0.70 numerical aperture 60× 
objective. Eight images (4 bright field and 4 fluorescent) were taken for each well. 
Fluorescent images were acquired using a texas red filter with excitation and emission 
wavelengths of 562/40 nm and 624/40 nm, respectively, with an exposure time of 100 ms. 
Both negative and positive controls were included in every two columns to account for 
fluorescence decrease across the 96-well plate due to gradual decrease in intracellular 
accumulation of probe over time. intracellular int fluorescence. Screening was performed 
in 3 independent experiments. Fluorescent images were analyzed using the MetaXpress 
software (version 5.10.41, Molecular Devices). Segmentation of fluorescent objects on the 
texas red channel was achieved using a custom application module based on the ‘Find 
Blobs’ module. The custom module enables differentiation of fluorescent accumulation 
from background and artifacts via segmentation masks based on set parameters for object 
size.  
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2.4 Doxorubicin accumulation assay using confocal microscopy 
Confocal microscopy was used to confirm inhibition of MRP1 mediated doxorubicin 
efflux.  HEK293T cells were plated on poly-D-lysine-coated cover glass placed in a 6-well 
plate at a density of 5 × 105 cells/well in 2 mL culture medium. Cells were transiently 
transfected with an MRP1-GFP expression vector after 24 hours using jetPRIME 
Transfection Reagent (Polyplus-transfection SA, Illkirch, France) according to the 
manufacturer’s protocol. After 48 hours,  cells were pre-treated with 10 µM test compound 
for 30 min, before incubation with doxorubicin (10 µM) for 1 h. Cells were maintained in 
buffer (4.5 % glucose, 10mM HEPES, PBS containing Ca2+ and Mg2+ ) as intracellular 
fluorescence  was visualized using a iMIC digital microscope (TILL Photonics GmbH, 
Gräfelfing, Germany) equipped with a 1.35 numerical aperture 60x oil-immersion 
objective. Excitation was done at 488 nm for GFP and doxorubicin, with emission bands 
of 475/42 and 605/64 nm, respectively. Images were processed using ImageJ (NIH, 
Bethesda, MD). 
 
2.5 Flow cytometry-based CRO-9 accumulation assay  
MRP1 mediated efflux of CRO-9was determined in the presence/absence of test 
compounds using flow cytometry. This was to quantitatively affirm the inhibition activity 
of drugs identified in the screening assay . H69AR cells were prepared in serum-free 
culture medium to a density of 7 × 105 cells/mL. One mL of cells was incubated with test 
compounds (10 µM) at 37 °C for 10 min after which 0.25 µM of CRO-9was added for an 
additional 30 min. DMSO concentration was maintained at 0.2% (v/v). Efflux activity of 
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MRP1 was stopped by adding ice-cold PBS buffer. Cells were then collected, washed with 
cold PBS and resuspended in ice-cold PBS containing 1% formaldehyde. Intracellular 
fluorescence of CRO-9was detected by BD Accuri C6 flow cytometer (BD Biosciences, 
San Jose, CA) equipped with 488nm and > 670nm for excitation and emission respectively. 
Fluorescence intensity was collected as mean of 10,000 events. Treatments were performed 
in duplicate and repeated in 3 independent experiments.   
 
2.6 Membrane vesicle preparation  
Membrane vesicles were prepared as described in Loe et al., [20] with modifications. 
Frozen cell pellets of HEK293/pcDNA 3.1 and HEK293/MRP1 were thawed and 
suspended containing 50 mM Tris.HCl, pH 7.4, 250 mM sucrose, 0.25 mM CaCl2, and 1x 
complete protease inhibitors (Santa Cruz Biotechnology, Dallas, TX). Cell disruption was 
achieved via nitrogen cavitation at 450 psi for 5 min. The resultant lysates were 
supplemented with 1mM EDTA and centrifuged at 500 × g at 4 °C for 10 min. The 
supernatant was collected twice by resuspending cell pellets and repeating centrifugation.  
Pooled supernatant was layered over 35% (w/w) sucrose containing 10 mM Tris.HCl, 
pH7.4, and 1 mM EDTA and centrifuged at 25,000 rpm at 4 °C for 1 h in a SW28 rotor 
(Beckman Coulter, Brea, CA). The opaque membrane interface formed was collected and 
washed twice by ultracentrifugation. The membrane pellet obtained was further 
resuspended in transport buffer (50 mM Tris.HCl, pH 7.4, and 250 mM sucrose) and passed 
20 times through a 27-gauge needle for vesicle formation. Protein concentration was 
determined using Quick Start Bradford Protein Assay (BioRad, Hercules, CA). 
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2.7 Membrane vesicular transport assay 
A rapid filtration technique was used to measure the ATP-dependent transport of 
[3H]E217βG  into MRP1 enriched inside-out membrane vesicles [20]. The vesicles (2 µg 
protein) were incubated with 400 nM/20 nCi [3H]E217βG for a minute at 37°C in a 30-µL 
reaction mixture containing 4 mM AMP or ATP, 10 mM MgCl2, and test compound in 
transport buffer (250 mM sucrose and 50 mM Tris-HCl, pH 7.4). Total DMSO 
concentration was kept at 0.3%. Reaction was stopped by the addition of ice-cold buffer 
and resulting mixture transferred to a 96-well MultiScreenHTS-FB plate (EMD Millipore, 
Billerica, MA). Filter membranes were washed 4X with 200 µL ice-cold suspension buffer 
under vacuum aspiration. Radioactivity retained on the membranes was measured with Tri-
Carb 4810TR liquid scintillation counter (PerkinElmer, Waltham, MA). ATP-dependent 
uptake was calculated by subtracting the uptake in the presence of AMP from the uptake 
in the presence of ATP. Treatments were performed in triplicates. 
 
2.8 Drug sensitivity Assay 
The sensitivity of H69 and H69AR cells towards multiple chemotherapeutic drugs 
(vincristine and SN-38) and the ability of test compounds to reverse the resistance of 
H69AR cells against these drugs were analyzed using the MTT colorimetric assay. H69 
and H69AR cells were seeded in 96-well plates (CellBIND®, Corning) at 2.5 × 104 cells 
per well in 100 µL culture medium and allowed to attach overnight. The cells were 
pretreated with 50 µL of test compounds in culture medium and incubated for an hour. 
Subsequently, 50 µL of cytotoxic drugs (vincristine and SN38) at varying concentrations 
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was added to the cells. Final DMSO concentration was maintained at 0.2%. Cells were 
further incubated for 96 h. At the end of the incubation period, 100 µL of culture medium 
was carefully removed and cells were treated with MTT (0.5 mg/mL) for 4 h. The formazan 
crystals were dissolved by the addition of 100 µL of 15% SDS containing 10 mM HCl and 
absorbance at 570 nm were recorded using a Hidex Sense Beta Plus plate reader (Turku, 
Finland). Treatments were performed in triplicates and repeated three times. 
 
2.9 High content screening data analysis  
The MetaXpress software was used for analysis. The mean fluorescent intensity of each 
well was obtained from averaging the fluorescent intensities of the segmentation mask of 
4 captured images. The use of segmentation mask prevents the inclusion of background 
fluorescence as cells are defined. The relative inhibition of each test compound on CRO-
9efflux was determined for each well using the following equation:  
%	𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 		𝑋 𝑇 − 	𝑋 𝐶𝑅𝑂 − 9  	𝑋 𝑀𝐾-571 − 	𝑋 𝐶𝑅𝑂 − 9   × 100 , 
where X represents the average fluorescent intensities and T represents the test compound. 
Both positive and negative controls were placed in every two columns and used for the 
determination of the percent inhibition for compounds within the same columns. The Z’-
factor, a parameter commonly used to infer the versatility and variation of an assay [21] 
was determined with the following equation: 
	𝑍 ′ -𝑓𝑎𝑐𝑡𝑜𝑟 = 1 − 	3		𝜎 𝑀𝐾-571 + 	𝜎 𝐶𝑅𝑂 − 9   		𝜇 𝑀𝐾-571 − 	𝜇 𝐶𝑅𝑂 −
9   , 
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where σ and μ represent the standard deviations and means, respectively.  
2.10 Statistical analysis 
Statistical analyses were performed using GraphPad prism (GraphPad Software, San 
Diego, CA). The differences between mean values were analyzed using linear mixed model 
analysis. Sidak correction was applied for multiple comparisons. For all analyses, 
differences were considered significant at P value lower than 0.05.  
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3.0 Results 
3.1 Assay development and optimization 
We recently reported the development of an imaging-based high content assay for 
screening for MRP1 inhibitors. This system is more robust and efficient as compared to a 
fluorescent microplate reader or flow cytometer as it eliminates background fluorescence 
or artifacts by using the custom module to identify cells. This assay originally developed 
with calcein-AM [18] had been adapted using doxorubicin [19]. The assay using 
doxorubicin as a fluorescent reporter identified more inhibitors than calcein-AM after 
screening the same anti-cancer library. MRP1 as a drug transporter has multiple binding 
sites thus identification of inhibitors is limited to the fluorescent probe used. In this study, 
High-Content Screening System, which employs advanced image analysis and quantitation 
tools, was used to develop an imaging-based high-throughput efflux assay for MRP1using 
CRO-9 as probe. H69 cell line and its MRP1-overexpressing derivative H69AR cell line 
were used for the development and optimization of this assay. The parental H69 cells are 
expected to have higher intracellular accumulation of CRO-9 due to low expression of 
endogenous MRP1 as compared to H69AR. However, H69AR is expected to have lower 
intracellular accumulation of CRO-9 due to the efflux activity of MRP1 under similar 
experimental conditions. For optimization of the assay, both concentration and time 
dependent accumulation of CRO-9 were studied in both cell lines.  
As shown in Figure 3.1A, increased concentrations of CRO-9 yielded an increase in 
intracellular fluorescence. The intracellular accumulation of CRO-9 was remarkably higher 
in the parental H69 as compared to the H69AR in all tested concentrations. To confirm that 
the difference in fluorescence accumulation observed in both cell lines were due to MRP1 
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activity, MK571, an MRP1 inhibitor was introduced. MK571 did not affect CRO-9 
accumulation regardless of the incubation duration in H69 cell line (Figure 3.1B). In 
contrast, MK571 significantly increased intracellular fluorescence in H69AR by 
approximately 6-fold at 30 minutes of incubation as indicated in Figure 3.1C. 
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Figure 3.1 Concentration- and time-dependent accumulation of CRO-9 in H69 and 
H69AR cells. 
A. H69 and H69AR cells were treated with CRO-9 at various concentrations (10–300 nM) 
for 1 h. Representative images of CRO-9 treatment at 30, 100, and 300 nM are shown. The 
average fluorescence intensities derived from the fluorescent images were graphed and 
shown on the right. B. H69 cells were treated with 250 nM CRO-9 in the absence and 
presence of 50 µM MK571 for 30–90 min. Representative images of CRO-9 treatment at 
30, 60, and 90 min are shown. C. H69AR cells were treated with 250 nM doxorubicin in 
the absence and presence of 50 µM MK571 for 30–120 min. Representative images of 
CRO-9 treatment at 30, 60, and 90 min are shown. Data are representative of two 
experiments and shown as mean ± SD (n=3). 
 
3.2 Anti-cancer compound library screening for MRP1 inhibitors 
After optimization of the high content assay with CRO-9, a 386 anti-cancer library under 
clinical trials of 12 different cancer types was screened for inhibitors of MRP1. Screening 
was done in a 96-well format in triplicates. Treatment with 50 µM MK571 (a commonly 
used MRP1 inhibitor) was considered as 100%MRP1 inhibition for calculating percent 
inhibition for the test compounds. Three independent screening experiments were done 
using the 96-well format. The relative MRP1-inhibitory activities of the test compounds 
from three independent experiments are represented as a 3D scatter plot (Fig. 3.2). The 
assay had good reproducibility with a correlation range of 0.72-0.78 between any two given 
experiments. The quality and performance of the assay were also assessed by calculating 
the Z’-factor from the experiments. The average Z’-factor across all plates was 0.51, 
indicating a good assay performance. A positive hit was defined as a compound with ≥ 
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50% mean percent inhibition. With this threshold value, we identified 50 hit compounds 
indicated by orange dots in Figure 3.2. Ten compounds out of the 50 were identified in 
previous studies in our lab using calcein-AM [18] and doxorubicin [19] as fluorescent 
reporters. Seventeen out of the remaining forty compounds were exclusive to studies using 
doxorubicin as fluorescent reporter. The twenty-three compounds that had not been 
identified in either studies were chosen for further studies.  
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Figure 3.2 Performance of the imaging-based MRP1-mediated CRO-9 accumulation 
screening assay. 
Screening of the anti-cancer compound library was performed in three independent 
experiments at a compound concentration of 10 µM. The relative inhibitory activities of 
each compound were calculated and displayed as a 3D plot. Orange dots represent 
compounds with a mean percent inhibition of ≥50%. The table below the plot shows 
correlation coefficients between any two experiments. 3D scatter plot was generated using 
SigmaPlot 12.0 and correlation coefficients were calculated using MS Excel.  
 
3.3 Validation of MRP1 inhibitors  
To qualitatively evaluate compound effect on doxorubicin efflux, HEK293T cells were 
transiently transfected with MRP1-GFP vector and the inhibitory effect of the test 
compounds on MRP1 activity was visualized using confocal microscopy. As shown in 
Figure 3.3A, cells treated with DMSO showed high doxorubicin accumulation in the nuclei 
of non-transfected cells, while cells expressing MRP1-GFP displayed very low 
doxorubicin accumulation. MRP1-mediated efflux of doxorubicin was reduced by MK571 
(50 µM), which was used as the positive control. All the test compounds (10 µM) induced 
doxorubicin accumulation in MRP1-expressing cells to a certain extent, ranging from 
strong, moderate to mild. Drugs such as, BIBR 1532, bosutinib, WP1130 and nutlin-3 
showed strong inhibition, while GSK11202122, PF562271, ZSTK474, ponatinib and 
NU7441 showed moderate to mild inhibition. For a more quantitative assessment of hit 
compounds, flow cytometry was done. To this end H69AR cells were pre-treated with the 
test compounds for 10 minutes prior to incubation with CRO-9 for 30 minutes. As shown 
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in Figure 3.3B, MK-571 at 50 µM enhanced doxorubicin accumulation in H69AR cells by 
3-fold. All hit compounds (10 µM) except evista, gefitinib, KU-0063794, and NU7441 
significantly increased CRO-9 accumulation in H69AR cells by 1.6–2.8-fold. 
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Figure 3.3 Validation of MRP1-inhibitory activity of identified hit compounds.  
A. HEK293 T cells transiently transfected with MRP1-GFP (green) were pre-treated with 
10 µM test com- pounds for 30 min, before treatment with doxorubicin (red) at 37 °C for 
1 h. Images were acquired using confocal microscopy. GFP and doxorubicin were excited 
at 488 nm, and detected at 475/42 and 605/64 nm, respectively. B. H69AR cells were pre-
treated with 50 µM MK571 or 10 µM test compounds for 10 min before treatment with 
250 nM CRO-9 at 37 °C for 30 min Fluorescence intensities of intracellular doxorubicin 
were detected using flow cytometry, with excitation and emission wavelengths of 488 and 
610/20 nm, respectively. Data are combined from two experiments and presented as mean 
± SEM. *, p value lower than 0.05 compared with control 
 
3.4 Effects of hit compounds on MRP1 mediated E217βG vesicular uptake 
Due to the essential physiological role of MRP1 in tissue defense, we were interested in 
evaluating our hits compounds on MRP1-mediated transport endogenous MRP1 substrates. 
For this purpose, we employed membrane-based vesicular uptake assay for E217βG, a 
glucuronide conjugate and a prototypical physiological substrate of MRP1 Membrane 
vesicles were prepared from HEK293/pcDNA 3.1 and HEK293/MRP1 cells. The uptake 
of [3H] labelled E217βG was measured to evaluate the effect of potential MRP1 modulators 
on E217βG efflux. As shown in Figure 3.4, ATP-dependent uptake of [3H]E217βG into 
HEK293/pcDNA3.1 (vector control) membrane vesicles was less than 1% of uptake by 
HEK293/MRP1 membrane vesicles. Transport of [3H] E217βG into HEK293/MRP1 
membrane vesicles was reduced by 94% with 10 µM MK571. Among the test compounds, 
evista, GSK1120212, MK-0752 and WIKI4 inhibited [3H]E217βG uptake by more than 
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50%, while CW069, gefitinib, KU-0063794, KU-55933, and LY2603618 showed little to 
no inhibition of [3H]E217βG transport uptake into HEK293/MRP1 membrane vesicles. 
 
 
 
Figure 3.4 Effects of test compounds on [3H]E217βG uptake into MRP1 expressing 
membrane vesicles. 
Membrane vesicles were prepared from stable HEK293/ pcDNA3.1 and HEK293/MRP1 
cells. Membrane vesicles (2 µg protein) were incubated with 10 µM test compounds. 
Reactions were performed using 400 nM/20 nCi [3H]E217βG at 37 °C for 1 min. 
Radioactivity retained on membrane vesicles was quantified using liquid scintillation 
counting. Data were combined from two experiments and presented as mean ± SEM, * p 
value lower than 0.05 compared with control. 
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3.5. Resistance reversal by selected MRP1 inhibitors 
Multidrug resistance is a major barrier to the success of chemotherapy. We therefore 
wanted to verify if the identified anticancer hit compounds had the ability to reverse 
resistance mediated by MRP1. Drugs that had this ability could be useful in clinical 
combinatorial therapies. Six potential drug hits (GSK650394, KU-0063794, LY2603618, 
MK0752, NU7441, ZSTK474) were selected for reversal studies based on available data. 
The ability of test compounds to reverse MRP1 mediated resistance in H69AR lung cancer 
cells against vincristine and SN38 was evaluated. These cytotoxic agents are known 
substrates of MRP1 with different chemical classifications and mode of actions.  
First, concentration-response was conducted for selected drug hits to evaluate the 
cytotoxicity profile of these compounds in H69AR (data not shown). Selected hit 
compounds at non-cytotoxic concentrations were then administered in combination with 
increasing concentrations of vincristine or SN38 to determine the ability to reverse 
resistance in H69AR cells. As shown in Figure 3.5 MRP1-over- expressing H69AR cells 
(solid red) showed MDR and as expected exhibited much lower sensitivity towards each 
of the cytotoxic cancer drugs than H69 cells (dotted red). IC50 values and fold resistance of 
the parental H69 and the MRP1-overexpressing derivative H69AR cells treated with 
vincristine or SN38 with or without the selected compounds are presented in Table 3.1.  
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Table 3.1  The effects of selected MRP1 inhibitors on the IC50 values of vincristine and 
SN38 
Cell line/Treatment Vincristine SN38 
 IC50 a (nM) Fold resistance 
b 
IC50 a (µM) Fold resistance 
b 
H69 0.861 ± 0.003  1.00 0.0030 ± 
0.0004  
1.00 
H69AR  23.35 ± 3.4 27.11 0.71 ± 0.04 236.90 
H69AR + MK571 10 µM 9.33 ± 1.43  10.83 0.28 ± 0.04  94.89 
H69AR + GSK650394 10 
µM 
14.96 ± 0.77  17.37 0.45 ± 0.05  151.57 
H69AR + KU-0063794 0.1 
µM 
12.55 ± 1.11 14.58 0.46 ± 0.04  153.83 
H69AR + LY2603618 10 µM 11.12 ± 0.30  12.92 0.0055 ± 
0.0006  
1.84 
H69AR + MK-0752 10 µM 11.98 ± 0.23  13.92 0.52 ± 0.12  171.96 
H69AR + NU7441 10µM 13.04 ± 0.52  15.14 0.389 ± 0.001 129.66 
H69AR + ZSTK474 2 µM 11.76 ± 0.82  13.66 0.03 ± 0.01 9.74 
aMean ± SEM of n ≥ 3 independent experiments.  
bFold resistance is the ratio between IC50 value of each treatment and IC50 value of 
vincristine and SN38 alone in H69 cells. 
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Figure 3.5 Reversal of drug resistance towards vincristine and SN38 in H69AR cells by 
selected MRP1 inhibitors. 
A. H69 and H69AR cells were treated with vincristine at increasing concentrations in the 
absence and/or presence of selected MRP1 inhibitors. B. H69 and H69AR cells were 
treated with SN38 at increasing concentrations in the absence and/or presence of selected 
MRP1 inhibitors. A and B. MK571, GSK650394, LY2603618, MK-0752, NU7441, were 
at 10 µM, KU-0063794and ZSTK474were at 0.1 µM and 2 µM respectively. Cell viability 
was evaluated with MTT after 72 h. Data are representative of three experiments and 
presented as mean ± SD (n = 3). 
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Figure 3.6 Chemical Structures of the selected 23 hit compounds  
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4.0 Discussion 
Chemotherapy is the prevalent form of treatment for advanced stages of most types of 
cancer. Factors affecting the success of chemotherapy include multidrug resistance (MDR) 
and toxicity. MDR is known to be a major cause of relapse in chemotherapy. Energy 
dependent efflux of anticancer drugs by mainly P-gp, MRP1 and BCRP have been reported 
to be a significant contributing factor to the development of MDR due to their key roles in 
drug disposition of anticancer therapeutics [3, 22]. Conventional anticancer drugs such as 
doxorubicin, vincristine, etoposide, methotrexate and carboplatin target basic and essential 
cellular processes in their mechanism of action. Thus, conventional chemotherapeutics are 
not specific and results in increased toxicity in patients. Current and emerging 
chemotherapeutics are drugs that show specificity in cancer cell type and often target 
specific signaling pathways associated with specific cancers. However, with the ability of 
drug transporters such as MRP1 to interact and affect the bioavailability of a broad 
spectrum of drugs, it is essential to profile interactions of new and emerging 
chemotherapeutics with drug transporters. In cancers such as childhood neuroblastoma, 
ovarian cancer [23], acute lymphoblastic leukemia [24], the overexpression of MRP1 has 
been linked to the poor survival rates of patients. Extensive literature on MRP1 also 
supports the potential use of MRP1 as a biomarker in non-small cell lung cancer (NSCLC) 
[25]. 
Current strategies to overcome ABC transporter mediated MDR include the co-
administration of transporter inhibitor with chemotherapeutics (combination therapy) or 
the use of anticancer drugs that are not substrates of MRP1. Several modulators have been 
developed and investigated over time for their inhibitory activity against MRP1-mediated 
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transport. Drugs such as indomethacin, probenecid, MK571, and ONO-1078 have been 
shown to inhibit MRP1 in vitro but the clinical significance has been uncertain due to 
toxicity and specificity related issues [26]. No potent and safe MRP1 modulator has been 
developed yet. In this study we investigated the interaction of MRP1 with a unique library 
of anti-cancer compounds currently under clinical trials targeting 12 types of cancers. 
MRP1 inhibitors from this library has the potential of being used to reverse MRP1 
mediated drug resistance in cancers where MRP1 is significantly overexpressed. They can 
also be used to improve efficacy of other known anticancer agents which are substrates of 
MRP1.  
For this study, we successfully developed and validated a high content imaging-based 
uptake assay for MRP1 transport activity using CRO-9 as a fluorescent reporter substrate. 
We are the first to discover CRO-9 as a substrate of MRP1 and develop a novel assay using 
this dye. Screening of a 386 unique anticancer library with CRO-9, we identified 23 MRP1 
inhibitors which were missed by a similar assay using calcein-AM or doxorubicin. The 
assay exhibited a high correlation (0.72-0.78) between any two experiments among the 
three independent screening experiments. The high quality, performance and range of this 
screening assay were demonstrated by a Z’-factor of 0.51 across all plates. High content 
imaging used in this study offers an advanced image analysis tools which enables the 
elimination of non-specific and background fluorescence. The assay also allows the 
simultaneous detection of cell-permeable, non-toxic and potent inhibitors. Majority of 
inhibitors identified previously from the 386-unique anticancer library using either calcein-
AM or doxorubicin as fluorescent reporter were also identified using CRO-9. With 
extensive biochemical and structural literature suggesting that MRP1 has multiple distinct 
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substrate binding sites [27, 28], our data implies that CRO-9 may have overlapping binding 
sites with calcein-AM and doxorubicin and an additional exclusive biding site as well. 
These differences observed can be due to structural differences between CRO-9, 
doxorubicin and calcein-AM.  
Among the 50 hit compounds identified as MRP1 inhibitors in this study, 10 compounds 
were common with studies using calcein-AM based screening assay and doxorubicin. An 
additional 17 compounds including alisertib and amutavinib which were reported for the 
first time to interact with an ABC transporter using doxorubicin were also identified using 
CRO-9. Thus, we focused on characterization of the 23 hit compounds exclusive to CRO-
9. Among the hit compounds exclusive to CRO-9, Nutlin 3, ZSTK474, ibrutinib and evista 
has been reported to inhibit the activity of MRP1 transport [29, 30, 4, 31]. Out of the 23 
inhibitors identified, 19 have not been previously reported to inhibit the transport by MRP1. 
Nutlin 3a an enantiomer of nutlin 3 has been reported to affect the P-gp and BCRP mediated 
transport but not MRP1 [29, 32]. In validating our hit compounds as MRP1 inhibitors, both 
cell-based assays and vesicular transport assays were employed. Nine drugs (AUY922, 
CW069, gefitinib, GSK650394, ibrutinib, KU55933, LY2603618, WP1130 and ZSTK474) 
significantly affected MRP1 mediated transport in cell-based assays measuring CRO-9 
efflux but did not affect MRP1 mediated uptake of E217βG in enriched membrane vesicles. 
This demonstrated the substrate selective inhibition ability of some compounds identified 
as inhibitors in this study. Compounds that show substrate selective inhibition of MRP1 
may be useful in specialized treatment of MDR tumors. 
Six of the inhibitors identified in this study (GSK650394, KU-0063794, LY2603618, 
MK0752, NU7441 and ZSTK474) were evaluated for their ability to reverse MRP1 
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mediated resistance of MRP1-overexpressing lung cancer cell line (H69AR) against 
vincristine and SN38. We also sought to examine whether reversal of resistance by selected 
drugs were substrate specific. Vincristine and SN38 are MRP1 substrates with different 
chemical class/family and cellular mechanism. Among the 6 drugs evaluated, LY2603618 
and ZSTK474 were the most effective in reversing MRP1- mediated resistance by reducing 
fold resistance to vincristine from 27.11 to 12.92 and 13.66 respectively. For MRP1-
mediated resistance of H6AR to SN38, LY2603618 and ZSTK474 reduced the fold 
resistance from 236.90 to 1.84 and 9.74 respectively. LY2603618, a novel MRP1 inhibitor 
identified in this study is a Chk (Checkpoint kinase) inhibitor which has been used in 7 
clinical trials as of September 20th, 2019 (clinicaltrials.gov) for studying the treatment of 
solid tumors, advanced cancer, pancreatic neoplasms [33], and non-small cell lung cancer 
(NSCLC) [34]. LY2603618 has been shown to increased cisplatin sensitivity in 
osteosarcoma, however the interaction of the drug with ABC transporters including MRP1 
has never been reported. LY2603618 in our study successfully reduced fold resistance of 
H69R to vincristine by half (reduced from 27-fold resistance to approximately 13-fold). It 
also reversed resistance to SN38 almost completely by decreasing the fold resistance from 
237-fold difference to 1.8-fold which is similar to the non-resistant parental cell line (H69). 
With MRP1 being overexpressed in cancers such as non-small lung cancer [25], 
LY2603618 holds great promise in the treatment of subpopulation of NSCLC patients who 
have upregulated MRP1 levels. 
ZSTK474, a potent phosphoinositide 3-kinase (PI3K) inhibitor identified in this study has 
been reported to inhibit P-gp, MRP1 and BCRP [35]. It has been reported to have 
synergistic effect when combined with imatinib in multidrug resistant K562/A02 cells [36]. 
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ZSTK474 has also been shown to reverse MDR resistance in HL60/HL60ADR cells [30] 
which is consistent with our findings. In our study, ZSTK474 was much more efficient in 
reversing resistance to SN38 (reduced approximately 237-fold resistance to approximately 
10- fold resistance) as compared to vincristine (27-fold resistance to approximately 14-fold 
resistance). 
GSK650394, a serum-regulated kinase 1 (SGK1 inhibitor) which has been investigated for 
its potential as therapeutic treatment of prostate cancer [37] and colorectal cancer [38] is 
reported for the first time to inhibit and reverse MRP1 mediated resistance of H69AR to 
vincristine and SN38. KU-0063794, an mtor inhibitor was able to sensitize H69AR to 
vincristine (IC50 reduced from 23.4 to 12.55 nM ) and SN38 (reduced IC50 from 0.71 to 
0.46 µM). Interactions of KU-0063794 with ABC transporters has also not been reported. 
NU7441 is a potent DNA-PK inhibitor has been reported to inhibit P-gp mediated efflux 
of doxorubicin [39] but has not been reported for its inhibitory activity against MRP1. 
Another novel inhibitor identified in this study (MK0752) has been in nine phase I /phase 
II clinical trial for combination therapies for various cancers (clinicaltrials.gov). For 
advanced metastatic breast cancer, the drug is combined with docetaxel whiles 
combination with gemcitabine is being done for patients with pancreatic ductal 
adenocarcinoma. Although reversal of MRP1 resistance has not been demonstrated, 
MK0752 is a known gamma secretase inhibitor that targets the notch signaling pathway 
[40]. Some studies have shown that chemotherapy drugs such as doxorubicin induces a 
Notch 1 dependent upregulation of MRP1 [41, 42]. In this study, MK0752 sensitized 
MRP1-overexpressing H69AR cells to vincristine (reduced IC50 from 23.4 to 11.98 nM) 
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and SN38 (reduced IC50 from 0.71 to 0.52 µM). The effect on MRP1 mediated resistance 
observed may therefore be due to the effect of the drug on the notch signaling pathway. 
In summary, we demonstrated the efficacy of using CRO-9 as a fluorescent reporter in a 
high content imaging-based assay to profiling interactions with MRP1. Anti-cancer agents 
which were identified as inhibitors have the potential of being used in combinational 
therapy to increase the efficacy of other chemotherapeutic drugs. They can also be explored 
in treatment of subpopulation of patients with multidrug resistance cancers where MRP1 
is prominently expressed.   
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RELEVANT CONTRIBUTIONS  
1.0 Scope  
This chapter entails relevant contributions to other studies in our research group. The 
research in this chapter is categorized into two projects. The first project was titled 
“Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and Exhibit 
Selective Cytotoxicity in MRP1-overexpressing Cells” and published in Drug Metabolism 
and Disposition [1]. In this project, the focus of the paper was showing the selective 
cytotoxicity of calcitriol and calcipotriol toward MRP1-overexpressing cells which could 
be eliminated with MRP1 inhibitor MK571. Data obtained indicated a potential role of 
calcitriol and its analogs in targeting malignancies in which MRP1 overexpression is 
prominent and contributes to MDR. 
The second project, titled “Development of Novel Intramolecular FRET-Based ABC 
Transporter Biosensors to Identify New Substrates and Modulators” published in 
Pharmaceutics [2]. The objective of the research was to develop a functional recombinant 
MRP1 biosensor protein which could determine compound interactions with MRP1. The 
clone MRP1-GR-881 was used in screening 40 novel anti-cancer drugs and identified 10 
hits that potentially directly interact with MRP1 and could be substrates or modulators. 
This provides a valuable tool in profiling of drug libraries for interaction with MRP1. 
Knowledge of drug-MRP1 interactions can provide useful information to improve the 
efficacy and reduce the toxicity of various therapies. 
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Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and 
Exhibit Selective Cytotoxicity in MRP1-overexpressing Cells 
1.1 Introduction 
Collateral sensitivity is a phenomenon in which the development of resistance toward a 
cytotoxic agent in the cells simultaneously confers a greater sensitivity to an alternate agent 
[3]. The possibility of exploiting collateral sensitivity in cancers where P-gp, MRP1, and 
BCRP is overexpressed is garnering heightened interest [3]. The underlying mechanisms 
for collateral sensitivity are yet to be delineated but several putative mechanisms have been 
proposed, including the generation of reactive oxygen species, change in cellular energy 
levels, extrusion of essential endogenous substrate, and membrane perturbation in the 
resistant cells [4]. Calcitriol (1, 25-dihydroxyvitamin D3), the active metabolite of vitamin 
D3, is a potent hormone which regulates numerous physiologic processes in human body. 
Calcitriol is conventionally recognized for its role in bone development via the absorption 
of calcium and phosphorous [5]. Accumulating data recently shows other non-skeletal 
functions in conditions such chronic kidney diseases [5]. In cancer, multiple evidence from 
epidemiologic and preclinical studies suggest that calcitriol reduces cancer risk and 
progression. However, evidence from randomized clinical trials has been lacking or 
inconclusive [6,7]. Nonetheless, the interest in the use calcitriol for the prevention and 
improvement of cancer and other diseases remains high and several large-scale clinical 
trials are underway to determine the effects of calcitriol on these major diseases [7]. 
Calcipotriol, a synthetic derivative of calcitriol is conventionally used in the treatment of 
psoriasis. However, it was also recently shown to be effective  immunotherapy  against 
early skin cancer when combined with 5 fluorouracil [8]. 
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In this paper, the focus of my research and contribution was to confirm that the 
hypersensitivity observed in MRP1 over expressive cell lines (H69AR and HEK/MRP1) 
after exposure to calcitriol and calcipotriol was due to the transport activity of MRP1. 
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1.2 Materials and methods 
1.2.1 Chemicals  
Calcitriol, calcipotriol, MK571,  and vincristine were purchased from Cayman Chemical 
(Ann Arbor, MI). Mitoxantrone, poly-D-lysine, thiazolyl blue tetrazolium bromide (MTT), 
and verapamil were obtained from Sigma-Aldrich (St. Louis, MO) whiles Ko143 were 
purchased from Tocris Bioscience (Avonmouth, Bristol, UK).  
 
1.2.2 Cell Lines and Cell Culture 
H69 and H69AR cells were purchased from  ATCC (Manassas, VA). HEK293/pcDNA3.1, 
HEK293/MRP1, HEK293/P-gp, and HEK293/BCRP were kindly gifted by Dr. Suresh V. 
Ambudkar (NIH, Bethesda, MD). HEK293 and H69 cell lines were cultured in DMEM 
(GE Healthcare, Marlborough, MA) and RPMI 1640 (ATCC), respectively, supplemented 
with 10% fetal bovine serum. H69AR cells were monthly exposed to 0.8 µM doxorubicin 
and cultured without drug for 1 week before use in experiments. Cells were cultured at 
37°C in a humidified incubator set at 5% CO2.  
 
1.2.3 Western Blot Analysis 
Cell lysates were prepared in RIPA buffer (Thermo-Fisher Scientific, Waltham, MA) 
supplemented with 1× Halt Protease Inhibitor Cocktail (ThermoFisher Scientific). Protein 
concentration was determined using Pierce BCA Protein Assay (ThermoFisher Scientific). 
Cell lysates (20 µg protein) were electrophoresed on 7.5% Mini-PROTEAN TGX gels 
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(BioRad, Hercules, CA) and transferred onto Immobilon PVDF membranes (EMD 
Millipore, Burlington, MA). Membranes were blocked for 1 hour at room temperature and 
incubated overnight at 4°C with monoclonal anti-MRP1 antibody (QCRL; Sigma) or anti-
α-tubulin antibody (Sigma-Aldrich) at 1:500 and 1:10000 dilutions, respectively. 
Secondary antibody incubation was performed using horseradish peroxidase-conjugated 
goat anti-mouse IgG (H + L) (ThermoFisher Scientific) for 1 hour at room temperature. 
Target proteins were detected using Western Lightning Plus-ECL, Enhanced 
Chemiluminescence Substrate (PerkinElmer) and imaged using a C-DiGit Blot Scanner 
(LI-COR Biosciences, Lincoln, NE). For protein expression comparison, protein band 
density was analyzed using the Image Studio Lite (LI-COR Biotechnology, Lincoln, NE) 
software and corrected for uneven sample loading and transfer using α-tubulin as the 
loading control. 
 
1.2.4 Cytotoxicity Assay 
Cell sensitivity to test compounds was analyzed using the MTT colorimetric assay. 
HEK293 was plated in 96-well plates (CellBIND; Corning) at 5 × 103 cells per well in 100 
µl culture medium and allowed to attach overnight. For treatment 100 µl of test compound 
of varying concentrations prepared in culture medium was added to the cells. DMSO 
concentration was maintained at 0.5%. For the effect of inhibitor on collateral sensitivity, 
50 µl of MK571 was added and incubated for 1 hour before the addition of varying 
concentration of calcitriol or Calcipotriol. For drug combination treatments in HEK293/P-
gp and HEK293/BCRP cells, 50 µl of calcitriol, calcipotriol, or control compounds were 
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added and incubated for 1 hour before 50 µl of cytotoxic drugs (vincristine or 
mitoxantrone) were added. Cells were incubated for 72 hours. At the end of the incubation 
period, 100 µl of culture medium was carefully removed, and cells were treated with MTT 
(0.45 mg/ml) for 4 hours. The formazan crystals were dissolved by the addition of 100 µl 
15% SDS containing 10 mM HCl and absorbance at 570 nm were recorded using a Hidex 
Sense Beta Plus plate reader (Turku, Finland) 
 
1.2.5 Statistical Analysis  
Statistical analyses were performed using IBM SPSS Statistics (IBM, Armonk, NY). The 
differences between mean values were analyzed using linear mixed model analysis. Sidak 
correction was applied for multiple comparisons. For all analyses, differences were 
considered significant at P value lower than 0.05.  
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1.3 Results 
Based on the strong modulatory activity of vitamin D analogues (calcitriol and calcipotriol) 
in cell and membrane-based assays, their interaction with MRP1 was further studied. 
Preliminary studies showed a hypersensitivity of MRP1-overexpressing cells toward 
calcitriol and calcipotriol. Data from the cytotoxic studies revealed a concentration-
dependent cytotoxic effect of calcitriol and calcipotriol, calcipotriol, with IC50 values of 
11.0 ± 0.7 and 8.9 ± 1.3 µM, respectively, in MRP1 over-expressing H69AR cells (Fig. 
4.1A; Table 4.1). However, the IC50 values for calcitriol and calcipotriol in the parental 
H69 cells were threefold higher than the resistant cell line. In HEK293/MRP1 cells, 
calcitriol and calcipotriol also exhibited a concentration-dependent cytotoxic effect, with 
IC50 values of 8.9 ± 1.3 and 6.0 ± 1.8 µM, respectively, which were lower than IC50 values 
in parental HEK293/pcDNA3.1 by four-fold. (Fig. 4.1B; Table 4.1).  
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Table 4.1 IC50 values derived from cytotoxicity assays 
Assay IC50 (µM)a 
 Calcitriol Calcipotriol 
Cytotoxicity   
H69 29.0 ± 1.2 * 23.9 ± 0.5 * 
H69AR (Control) 11.0 ± 0.7 8.5 ± 1.0 
H69AR + MK571 (10 µM) 16.4 ± 1.9 15.0 ± 1.1 
H69AR + MK571 (25 µM) 35.3 ± 2.2 * 36.3 ± 2.3 ** 
H69AR + MK571 (50 µM) 61.6 ± 1.0 ** 42.4 ± 1.0 ** 
   
HEK293/pcDNA3.1 33.4 ± 2.5 ** 23.3 ± 3.7 ** 
HEK293/MRP1 8.9 ± 1.3 6.0 ± 1.8 
HEK293/MRP1 + MK571 (10 µM) 11.7 ± 1.1 16.5 ± 0.1 
HEK293/MRP1 + MK571 (25 µM) 16.1 ± 0.5 * 23.6 ± 0.6 * 
HEK293/MRP1 + MK571 (50 µM) 35.3 ± 4.0 ** 27.5 ± 0.2 * 
a Mean ± SEM of n = 3 independent experiments 
* p < 0.05, ** p < 0.01 significantly different between indicated groups, calculated using 
linear mixed model with Sidak post hoc test.  
 
To test whether the observed collateral sensitivity is dependent on MRP1 activity, we 
measured the cytotoxicity of calcitriol and calcipotriol treatments in MRP1 over-
expressing H69AR and HEK293/MRP1 cells in the presence of 10 and 50 µM MK571 
(MRP1 inhibitor). Our results showed that collateral sensitivity of MRP1 over-expressing 
cell lines toward calcitriol and calcipotriol can be eliminated by MRP1 inhibitor MK571 
(Fig. 4.1; Table 4.1). By using inhibitor at 10 µM (partial MRP1 inhibition) and 50 µM 
(complete MRP1 inhibition) the data indicated that collateral sensitivity is proportional to 
the amount of active MRP1.  
* 
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Figure 4.1 Collateral sensitivity of MRP1-overexpressing cells toward calcitriol and 
calcipotriol.  
H69 and H69AR cells were treated with increasing concentrations of calcitriol or 
calcipotriol in the absence or presence of MK571 for 96 hours. (A). Similar experiments 
were performed using calcitriol or calcipotriol in HEK293/pcDNA3.1 and HEK293/MRP1 
cells in the absence or presence of MK571 for 72 hour (B). Cell viability was evaluated 
with MTT assay. Data are representative of three experiments and expressed as mean 6 
S.D. (n = 3). 
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1.3.1 Effects of calcitriol and calcipotriol on MRP1 protein expression levels.  
To investigate the effect of calcitriol and calcipotriol on the protein expression of MRP1, 
western blot was performed on HEK293/MRP1 and H69AR after treatment with 1 µM and 
10 µM of both compounds for 48 h. The protein expression levels of MRP1 in both cell 
lines were not significantly altered by 1 µM calcitriol and calcipotriol (data not shown). 
However, at an increased concentration of 10 µM, calcitriol lowered the protein expression 
in H69AR cells but not HEK293/MRP1 as shown in Figure 4.2. However, calcipotriol 
treatment at 10 µM concentration did not significantly change MRP1 expression levels in 
both cell lines.  
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Figure 4.2 Effects of calcitriol and calcipotriol on protein expression of MRP1 
Cells were treated with DMSO, calcitriol, or calcipotriol (10 µM) for 72 hours. (A) 
Immunoblot analysis of whole cell lysates prepared from indicated cell lines with indicated 
treatments was performed as described in the Materials and Methods section. Data are 
representative of three experiments. Mean MRP1 protein expression (S.E.M., n = 3) shown 
as a fold change of the DMSO-treated control is shown in (B). Protein band density was 
analyzed using the Image Studio Lite (LI-COR Biotechnology) software and corrected for 
uneven sample loading and transfer using a-tubulin as the loading control.  
 
1.3.2 Effects of Calcitriol and Calcipotriol on Drug Sensitivity of HEK293/P-gp and 
HEK293/BCRP Cells 
Previous results had shown that both calcitriol  and calcipotriol did not cause 
hypersensitivity in both HEK293/P-gp and HEK293/BCRP cells. Thus, we intended to find 
out if calcitriol or calcipotriol had the ability to reverse drug resistance observed in 
HEK293/P-gp and HEK293/BCRP against cytotoxic substrates of these cell lines. 
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HEK293/P-gp and HEK293/BCRP cells were treated with anticancer drugs vincristine and 
mitoxantrone, respectively, in the presence and absence of 10 µM calcitriol and 
calcipotriol. Verapamil (25 µM) and Ko143 (1 µM) were used as positive controls for P-
gp and BCRP, respectively. As shown in Figure 4.3, HEK293/P-gp and HEK293/BCRP 
cells exhibited significant drug resistance as compared with the vector control cell line 
HEK293/pcDNA3.1. Treatment with verapamil and Ko143 in HEK293/P-gp and 
HEK293/BCRP cells, respectively, reversed the resistance of the cells toward the 
anticancer agents. In both cell lines, co-treatment with 10 µM calcitriol significantly 
reversed the resistance of the cells to a certain extent. However, no significant reversal was 
observed in cells co-treated with 10 µM calcipotriol. 
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Figure 4.3 Effects of calcitriol and calcipotriol on drug sensitivity of HEK293/P-gp and 
HEK293/BCRP cells. HEK293/P-gp. 
(A) and HEK293/BCRP (B) cells were treated with increasing concentrations of vincristine 
and mitoxantrone, respectively, in the absence and presence of calcitriol or calcipotriol (10 
µM) for 72 hours. Verapamil (25 µM) and Ko143 (1 µM) were used as positive controls 
in HEK293/P-gp and HEK293/BCRP cells, respectively. HEK293/pcDNA cells were 
included as negative control for drug resistance. Cell viability was evaluated with MTT 
assay. Data are representative of three experiments and expressed as mean 6 S.D. (n =3).  
A B 
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1.4 Discussion 
This study reported for the first time that the active metabolite of vitamin D3, calcitriol, 
and its analog calcipotriol, cause selective cytotoxicity in MRP1-overexpressing, but not 
P-gp- and BCRP-overexpressing cell lines. Calcitriol was also capable of significantly 
reversing resistance of P-gp and BCRP over-expressive cell lines to vincristine and 
mitoxantrone respectively. Albeit, calcipotriol did reverse resistance but not significantly 
in both cell lines. The addition of MRP1 inhibitor MK571 abolished the hypersensitivity 
previously observed in H69AR and HEK/MRP1 cells. This confirmed that the collateral 
sensitivity in the cell lines was dependent on the transport activity of MRP1.  
Combinatorial approach in cancer therapy which involves combination treatment of 
modulators and cytotoxic anticancer agents has been the main approach in targeting ABC 
transporter related MDR. Currently, majority of clinical trials using this method has been 
conducted using P-gp modulators as P-gp is the most important ABC transporter involved 
in MDR. However, these modulators have yielded unsatisfactory results leading to 
skepticism about the feasibility and efficacy of modulators/inhibitors in reversing ABC 
transporter mediated MDR. [9, 10]. This has garnered sufficient interest in exploiting 
collateral sensitivity as a substitute of the use of modulators in clinical trials. Collateral 
sensitivity is a phenomenon where drug resistant cells exhibit hypersensitivity to alternate 
drugs  in comparison with non-drug resistant cells [3, 11]. MRP1-overexpressing H69AR 
and HEK293/MRP1 cells exhibited collateral sensitivity toward calcitriol and calcipotriol. 
This phenomenon was specific to MRP1-overexpressing cells as we did not observe any 
collateral sensitivity in HEK293/P-gp or HEK293/BCRP cells. The selective cytotoxic 
activity of calcitriol and calcipotriol to MRP1 over-expressing cells could be attributed to 
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a variety of reasons including stimulation of GSH efflux, up-regulation of apoptosis in a 
MRP1-dependant manner [12, 13, 14]. In addition, calcipotriol treatment at 1 and 10 µM 
did not affect the MRP1 protein levels in HEK293/MRP1 and H69AR cells, however 
calcitriol treatment at 10 µM reduced the protein expression level of MRP1 significantly 
in H69AR but not HEK293/MRP1. These differences could be due to the physiological 
differences in the cell lines as they were derived differently. H69AR cells were derived 
from doxorubicin selection of H69 cells and HEK293/MRP1 were obtained through stable 
transfection of HEK293 cells. 
In conclusion, the main focus of this study was to provide a new perspective to the 
application of calcitriol and its analogs in cancer treatment. Specifically, our work suggests 
the potential use of calcitriol and its analogs in selectively targeting tumors with the MDR 
phenotype conferred by MRP1-overexpression and provides the rational for sequential use 
of calcitriol and other anti-cancer agents to circumvent the development of MRP1- 
mediated MDR in clinical chemotherapy. Future work should be focused on designing 
calcitriol analogs with improved potency and validating the feasibility of applying the 
MRP1-selective effect of calcitriol in vivo.  
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Development of Novel Intramolecular FRET-Based ABC Transporter Biosensors to 
Identify New Substrates and Modulators 
1.0 Introduction 
Multidrug resistance protein 1 (MRP1) can efflux a wide variety of molecules including 
toxic chemicals, drugs, and their derivatives out of cells. Drug substrates of MRP1 include 
anti-cancer agents, antibiotics, anti-viral, and anti-human immunodeficiency virus (HIV) 
[15]. Efflux of these drugs can interfere with their sub cellular concentration thereby 
reducing drug efficacy. Although drug development involves many stages, time consuming 
and costly, a significant number of drugs still fail in clinical trials due to toxicity and 
inefficacy related issues [2]. Profiling of drugs with relevant drug transporters can help 
eliminate undesirable drugs at early stages of drug development to reduce economic 
burden. Profiling drug interactions with MRP1 can identify drugs at risk losing their 
efficacy as a result of MRP1 overexpression or useful novel inhibitors useful for clinical 
chemotherapy, especially in malignancies where MRP1 is overexpressed. 
Previously, we had engineered a two-color MRP1 construct which quantified 
intramolecular fluorescence resonance energy transfer (FRET) changes as an index of NBD 
conformational changes [16]. The underlying principle is that substrate binding results in 
conformational changes in the NDB. To identify novel substrates and modulators of MRP1 
by exploiting intramolecular fluorescence resonance energy transfer (FRET), we 
genetically engineered six different two-color MRP1 proteins by changing green 
fluorescent protein (GFP) insertion sites, while keeping the red fluorescent protein (RFP) 
at the C-terminal of MRP1.  
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1.2 Materials and methods 
1.2.1 Cell Lines and Cell Culture  
HEK293T (human embryonic kidney) cell line was donated by Dr. Adam Hoppe (South 
Dakota State University, Brookings, SD, USA). Cells were cultured in DMEM (GE 
Healthcare, Marlborough, MA) and supplemented with 10% fetal bovine serum. Cells were 
cultured at 37°C in a humidified incubator set at 5% CO2.  
 
1.2.2 Detection of MRP1 Localization  
HEK293T cells were plated on poly-D-lysine-coated cover glass placed in a 6-well plate 
at a density of 5 × 105 cells/well in 2 mL culture medium. Cells were transiently transfected 
with the six two-color MRP1 plasmids after 24 hours using jetPRIME Transfection 
Reagent (Polyplus-transfection SA, Illkirch, France) according to the manufacturer’s 
protocol. After 48 hours, cells were imaged an iMIC digital microscope (TILL Photonics 
GmbH, Gräfelfing, Germany) equipped with a 1.35 numerical aperture 60x oil-immersion 
objective whiles maintained in buffer (4.5 % glucose, 10mM HEPES, PBS containing Ca2+ 
and Mg2+). GFP and RFP were excited at 470 nm and 561 nm, respectively. Emissions of 
GFP and RFP were correspondingly achieved at 496–530 nm and 573–637 nm. All images 
were processed with the ImageJ software (NIH). 
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1.2.3 Doxorubicin Accumulation Assay  
HEK293T cells were plated at 5 × 105 cells/well in 2 mL of complete medium on a poly 
D-Lysine coated coverslip in a six-well plate. After 24 h, the HEK293T cells were 
transiently transfected with the six different two-color MRP1 constructs using jetPRIME 
transfection reagent according to manufacturer’s protocol. After 48 hours, cells were 
treated with 10 µM of doxorubicin and incubated for an hour. Cells were then maintained 
in buffer (4.5 % glucose, 10 mM HEPES, PBS containing Ca2+ and Mg2+) and imaged using 
an iMIC digital microscope (TILL Photonics GmbH, Gräfelfing, Germany) equipped with 
a 1.35 numerical aperture 60x oil-immersion objective. GFP and doxorubicin were excited 
at 470 nm wavelength, with emission bands of 480–530 nm for GFP and 570–605 nm for 
doxorubicin. RFP was excited at 561 nm with an emission band of 573–637 nm. Images 
were processed with ImageJ (NIH).  
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1.3 Results and Discussion 
1.3.1 Localization and Transport Activity of Two-Color MRP1 Proteins in Live 
Cells 
Fluorescent protein tags like GFP or RFP are usually fused at the amino-terminal or 
carboxyl-terminal, and do not often cause protein folding and trafficking issues. However, 
insertion of GFP within the coding sequence of MRP1 could potentially cause problems 
with the correct folding and trafficking of MRP1. Although all the two-color MRP1 
recombinant proteins showed the expected size, we wanted to verify that both fluorophores 
(GFP and RFP) matured properly and that the recombinant MRP1 proteins were folded, 
trafficked, and localized properly at the plasma membrane of cells. HEK293T cells were 
transfected with cDNA expression vectors encoding different two-color MRP1 proteins, 
and confocal microscopy was used to visualize the localization and expression of 
recombinant MRP1 proteins. Confocal images in Figure 4.4 indicated that all two-color 
MRP1 recombinant proteins except GR-648 localized properly at the plasma membrane. 
This construct was not included in further studies. The GR-859 recombinant protein 
showed partial mislocalization and intracellular retention, but the recombinant protein was 
predominantly localized at the plasma membrane 
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Figure 4.4 Localization and expression of two-color MRP1 proteins 
HEK-293 (human embryonic kidney) cells were plated on glass-bottom chambered 
coverslips. 
Fluorescent images were taken using a confocal microscope equipped with a 63× oil-
immersion objective. GFP and TagRFP were excited at 470 nm and 561 nm, respectively. 
Emission was collected at 480–530 nm for GFP and 580–669 nm for RFP. 
 
To determine if the two-color MRP1 recombinant proteins were functional, their transport 
activities were evaluated in live cells by measuring accumulation of the fluorescent anti-
cancer drug, doxorubicin, a well-known substrate of MRP1 [17]. HEK293T cells were 
transfected with cDNA expression vectors encoding different two-color MRP1 proteins, 
and confocal microscopy was used to visualize the accumulation of doxorubicin (Dox) 
inside the cells. Transiently transfected cells are expected to have a mixed population of 
cells, transfected and untransfected cells. Transfected cells will express the two-color 
MRP1 at the plasma membrane of cells whiles untransfected cells will not. Doxorubicin, a 
substrate of MRP1 executes its cytotoxic action in the nucleus where intercalates into 
DNA. Thus, cells with a functional MRP1 clone will exhibit a lower intracellular 
accumulation of doxorubicin in the nuclei as compared with cells with a non-functional 
MRP1. This disparity is due to the efflux of doxorubicin by a functional MRP1. 
Doxorubicin fluorescence was very low in cells expressing either GR-638, GR-881, GR-
888, or GR-905 (Figure 4.5). These results demonstrate that recombinant MRP1 proteins 
GR-638, GR-881, GR-888, and GR-905 were functionally active. In contrast, cells 
transfected with GR-859 showed high doxorubicin accumulation in the nucleus, indicating 
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that this recombinant protein was not functional, despite having the expected size and 
proper localization at the plasma membrane.   
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Figure 4.5 Doxorubicin (Dox) accumulation assay 
HEK293T cells were transiently transfected with six different two-color MRP1 constructs 
and incubated for 48 h, after which doxorubicin treatment was done. Images were taken 
using a confocal microscope equipped with a 63× objective. GFP and Dox were excited at 
470 nm wavelength using an Ar laser, with emission bands of 480–530 nm for GFP and 
573–637 nm for Dox. RFP was excited at 561 nm, and its emission was collected at 580–
669 nm. Data were collected from all three channels—GFP, RFP and Dox. RFP and Dox 
have significant emission wavelength overlap, explaining the membranous signal seen for 
the two-color MRP1 recombinant proteins in the Dox channel.  
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FINAL DISCUSSION AND GENERAL CONCLUSIONS 
Few ABC transporters are recognized as the key drug transporters to be assessed for their 
interaction with new drugs in the drug discovery process. They play a pivotal role in 
governing the transit of a broad spectrum of endogenous substrates and drugs across major 
organs and physiological barriers [1]. MRP1 is one of the most important ABC transporters 
which affects drug distribution. It mediates tissue defense in organs such as lung, skin heart, 
kidneys, small intestines and pharmacological barriers like blood brain, blood, testes and 
blood placental barrier. In addition to limiting absorption and bioavailability of drugs, 
MRP1 also regulates drug elimination into urine and feces [2]. MRP1 is overexpressed in 
a diverse range of cancers and has been implicated in poor survival rates in cancers like 
acute lymphoblastic leukemia [3], and ovarian cancer [4]. MRP1 may have the widest 
spectrum of substrates among all clinically significant ABC transporters (P-gp and BCRP). 
Cells that overexpress MRP1 are resistant to a variety of drugs including anthracyclines, 
camptothecins, antimetabolites, epipodophyllotoxins and vinca alkaloids [5]. Unlike P-gp, 
MRP1 does not transport taxanes [5]. Due to the variability in its clinical significance and 
wide substrate range, finding modulators/inhibitors for MRP1 has been more challenging 
than P-gp. This may be due to MRP1’s preference of interacting with anionic compounds 
[6]. Anionic compounds do not efficiently enter cells due to the hydrophobic nature of cell 
walls. As a result, higher doses may be required to attain enough intracellular concentration 
for effective inhibition. This increases the likelihood of toxicity in vivo. Organic anion 
inhibitors such as probenecid, sulfinpyrazone and indomethacin have been used in vitro to 
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inhibit MRP1. However, since their inhibition activity is not specific to MRP1 (includes 
all organic anion importers and exporters) they cannot be used clinically as an MRP1 
inhibitor [7]. MK571 was initially thought to be a specific inhibitor of ABC (MRP) sub 
family of ABC transporters [8]. It was later discovered to inhibit P-gp and BCRP and issues 
regarding toxicity has prevented its use in clinical trials [9]. Considerable efforts have been 
made to develop inhibitors in order to improve efficacy of anticancer drugs and reduce 
transporter mediated MDR. To date, no potent and safe MRP1 modulator has been 
developed and tested in clinical trials and efforts to find the ‘ideal’ drug candidate is 
ongoing. In this study we investigated the interaction of MRP1 with a unique library of 
anti-cancer compounds which is are undergoing clinical trials targeting 12 types of cancers 
using a high content imaging-based efflux assay. 
Over the years, one of the most widely used cell-based assays for assessment of compound 
interaction with ABC transporters has been the fluorescent substrate accumulation assay. 
This assay measures the intracellular accumulation of a fluorescent substrate in a 
transporter-overexpressing cell line in the presence or absence of test compounds. Assays 
using fluorescent probes to evaluate transporter activity are termed as dye extrusion assay 
or uptake assays [10]. The accumulation assay has been utilized to study the interactions 
of ABC transporters. The general principle of accumulation assays is the fluorometric 
determination of intracellular accumulation of a specific probe such as calcein-AM. This 
assay has been extensively used to study drug interactions with MRP1 [11, 12] and P-gp 
[13]. Calcein-AM easily gets into cells by passive diffusion  where it is cleaved by 
endogenous cellular esterases to form a hydrophilic non permeable fluorescent compound 
[10]. Since calcein-AM is a good substrate of MRP1 and P-gp, it has been used for high 
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throughput screening of inhibitors of ABC transporters. Some anticancer drugs such as 
doxorubicin and mitoxantrone are fluorescent and thus drug accumulation can be used to 
study efflux activity of ABC transporters. Detection and quantification of intracellular 
accumulation of fluorescent probe is typically determined by flow cytometry. One of the 
major disadvantages using flow cytometry or microplate readout is the inability to exclude 
non-specific and background fluorescence which may result in false positives. Also, the 
effect of cytotoxic drugs on cell viability cannot be simultaneously detected with inhibitory 
activity of the drug. 
In recent years, imaging-based high content screening (HCS) using automated microscope 
platform has gained increasing popularity in drug discovery field of research. HCS enables 
high-throughput imaging of single or multiple biological activities measured as intensity 
or spatial localization of fluorescent dyes or proteins in cells. HCS platforms offer unique 
advantages over traditional high throughput platforms. The key advantage is its ability to 
offer multiple readouts. The readout is typically a fixed endpoint based on object 
segmentation. Object segmentation allows definition of cells which minimizes background 
noise and facilitates automated analysis. Additionally, this imaging-based uptake assay is 
more sensitive than assays based on fluorescence plate reader, which is more suited for 
assays done in a homogenous condition. Moreover, cells can be imaged in situ without cell 
suspension preparations and multiple washing steps, which increase the processing time 
and limit the assay throughput. Furthermore, cell viability and density before and after 
treatment can be visually inspected to evaluate compound cytotoxicity, which may 
interfere with the assay. 
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Our research lab has previously screened a unique anticancer library for MRP1 inhibitors 
using a high content imaging-based assay which used calcein-AM as a fluorescent reporter. 
This assay identified 12 inhibitors of MRP1 after screening a library of 386 anticancer 
agents. Since MRP1 has distinct multiple binding sites, we decided to use other fluorescent 
reporters to screen the same library. In this study, our main objective was to develop, and 
validate a high content imaging-based efflux assay using doxorubicin and CRO-9 as 
fluorescent reporter substrates. We are confident that we are the first research group to use 
doxorubicin and CRO-9 as a reporter substrate since there is no available literature 
supporting that it has been previously used as a substrate in a high content screening or any 
other high-throughput screening assay to identify inhibitors of MRP1. The screening 
process in the doxorubicin assay identified a total of 28 inhibitors, which included 10 of 
12 inhibitors discovered previously with calcein-AM assay as well as 18 MRP1 inhibitors 
that were missed by the calcein AM-based screening. Eleven out of the 18 drugs were 
reported for the first time to inhibit MRP1 mediated transport. Notable among the inhibitors 
identified using doxorubicin were afatinib, celecoxib, doramapimod, mifepristone, MK-
2206 and rosiglitazone which showed the ability to reverse MRP1 mediated resistance of 
H69AR to vincristine, doxorubicin and etoposide.  The drugs showed varied extent of 
resistance reversal in all three substrates used. Mifepristone and doramapimod were most 
effective in reversal of resistance against vincristine while mifepristone and rosiglitazone 
had greater effect on re-sensitizing H69AR cells to doxorubicin. Celecoxib exhibited 
selective MRP1 inhibition by completely reversing resistance of H69AR to etoposide but 
not having similar effect with vincristine and doxorubicin. 
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The assay utilizing CRO-9 further identified inhibitors that were missed by both calcein-
AM and doxorubicin. A total of 50 MRP1 inhibitors including 19 inhibitors that have not 
been previously reported as inhibitors of MRP1 were identified. Though there were some 
inhibitors exclusive to the assay with doxorubicin as fluorescent reporter, 23 potential hits 
identified by CRO-9 were missed by doxorubicin. Selected drugs (GSK650394, KU-
0063794, LY2603618, MK0752, NU7441 and ZSTK474) were able to decrease the fold 
resistance of H69AR to vincristine and SN38. LY2603618 and ZSTK474 were the most 
effective in reversing the resistance of H69AR cells against vincristine and SN38. NU7441 
was much more effective in reversing resistance against SN38 as compared to resistance 
of H69AR to vincristine. Drugs identified in this study are being studied for the treatment 
of various cancers. From our findings some of these drugs hold great potential in the 
treatment of subpopulation of patients with malignancies where MRP1 is prominently 
expressed. 
With new test compounds and pharmacological libraries being developed against a wide 
range of diseases, it is important to develop screening methods with high specificity and 
reliability for identifying modulators of ABC transporters especially for transporters that 
are implicated in multidrug resistance phenotype such as MRP1. Consequently, the use of 
just one traditional in vitro screening method may prove problematic as the possibility of 
false negative results is increased due to relatively low sensitivity of these methods and 
selective inhibitory activity of some compounds. 
Taken together, we conclude that this high content imaging-based assay is effective in 
identifying novel modulators of MRP1. Based on the International Transporter Consortium 
(ITC) recommendation and increased literature supporting the role of MRP1 in the 
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development of MDR in cancer, we anticipate that our high content imaging-based assay 
will be a great alternative to traditional in vitro methods for pharmaceutical industries 
interested in profiling drug interactions with MRP1. In our opinion, there is a lot of 
potential in utilizing this high-content imaged assay developed in our laboratory as 
doxorubicin and CRO-9 seem to be good fluorescent reporters in screening for MRP1 
modulators. This assay also has the potential to aid in the investigation of compound effects 
on ABC transporter expression, trafficking, and function. For example, the expression and 
trafficking of ABC transporters, and how small molecules affect these cellular events, can 
be probed using antibodies in conjunction with reporter substrates described in this paper. 
This strategy can be applied on clinically relevant mutants of ABC transporters to screen 
for small molecules that can correct anomaly in their expression, trafficking, and 
degradation.   
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APPENDIX A 
Fluorescent substrates of ABC transporters and compounds shown to inhibit efflux 
  P-gp MRP1 BCRP 
BODIPY FL EDA 
Lasalocid Loxapine Nicardipine Lasalocid Lasalocid  
Mometasone Pimozide Pimozide Mometasone   
Nicardipine Verapamil Verapamil    
BODIPY FL Forskolin 
Loxapine Mometasone Nicardipine  Nicardipine  
Pimozide Nicardipine     
BODIPY FL Histamine Mometasone  Pimozide Mometasone Mometasone  
Nicardipine  Verapamil Nicardipine Nicardipine Pimozide 
BODIPY FL Prazosin 
Pimozide Mometasone Loxapine Nicardipine Mometasone Nicardipine 
Verapamil Nicardipine Mometasone Verapamil   
Loxapine      
BODIPY FL 
Thapsigargin 
Mometasone Loxapine Loxapine Nicardipine   
Nicardipine Verapamil Mometasone    
BODIPY FL Verapamil, 
HCl 
Loxapine Pimozide Loxapine Pimozide   
Mometasone Verapamil Mometasone Verapamil   
Nicardipine  Nicardipine    
BODIPY FL Vinblastine 
Mometasone Loxapine Mometasone Verapamil   
Nicardipine Verapamil Nicardipine    
Calcein AM 
Mometasone XR9576 MK-571 Nicardipine   
Nicardipine Pimozide Mometasone Pimozide   
CBIC2(3) (JC-1) 
Mometasone Pimozide Mometasone Pimozide Mometasone Pimozide 
Nicardipine  Nicardipine  Nicardipine  
CellTracker Orange 
CMTMR 
Mometasone Pimozide Nicardipine    
Nicardipine Verapamil Verapamil    
DiIC1(5) 
Mometasone Pimozide Mometasone    
Nicardipine  Pimozide    
DiNOC1(3) (JC-9) 
Mometasone Pimozide Mometasone Pimozide   
Nicardipine Verapamil Nicardipine Verapamil   
Loxapine  Loxapine    
DiOC2(3) 
Mometasone Pimozide Mometasone Pimozide   
Nicardipine Verapamil Nicardipine Verapamil   
Loxapine  Loxapine    
DiOC5(3) 
Mometasone Pimozide Mometasone Verapamil   
Nicardipine  Pimozide    
DiOC6(3) 
Mometasone Pimozide Pimozide    
Nicardipine Verapamil Verapamil    
DiSC3(5) 
Mometasone Pimozide Mometasone    
Nicardipine Verapamil     
Loxapine      
Doxorubicin Substrate  Substrate  Substrate  
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eFluxx-ID Gold Substrate  Substrate  Substrate  
eFluxx-ID Green Substrate  Substrate  Substrate  
ER-Tracker Green 
Mometasone  Nicardipine    
Nicardipine  Pimozide    
LDS 751 
Mometasone Pimozide     
Nicardipine Verapamil     
Loxapine      
MitoTracker Green FM 
Mometasone Pimozide Mometasone    
Nicardipine Verapamil Nicardipine    
Loxapine  Verapamil    
MitoTracker Orange 
CMTMRos 
Mometasone Pimozide     
Nicardipine      
Mitoxantrone 
Substrate  Substrate  Ko143 GF120918 
    FTC  
Pheophorbide A     Substrate  
Rhodamine 123 PSC833      
Rhodamine 6G chloride 
Mometasone      
Nicardipine      
Rhodamine B, hexyl 
ester, perchlorate (R6)  
Mometasone Pimozide Mometasone Pimozide   
Nicardipine      
SYTO 13 
Mometasone Pimozide Mometasone Pimozide   
Nicardipine Verapamil Nicardipine Verapamil   
Loxapine  Loxapine    
SYTO 16 
Mometasone Pimozide Pimozide    
Nicardipine      
SYTO 9 
Mometasone Pimozide Mometasone Verapamil   
Nicardipine  Nicardipine    
Tetramethylrosamine 
Chloride 
Mometasone Pimozide Mometasone Verapamil   
Nicardipine  Pimozide    
TMRE 
Mometasone      
Nicardipine      
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APPENDIX B 
Radioactive substrates of ABC Transporters  
P-gp MRP1 MRP2 MRP3 MRP4 BCRP 
[ring C, 
methoxy-3H]-
Colchicine 
[14C]-1-Chloro-
2,4-
Dinitrobenzene  
([14C]-CDNB) 
[14C]-1-
Chloro-2,4-
Dinitrobenzene  
([14C]-CDNB) 
[6,7-3H] 
Estradiol 17-
(β-d-
Glucuronide) 
([3H]-E217βG) 
[6,7-3H] 
Estradiol 17-
(β -d-
Glucuronide) 
([3H]-E217βG) 
[3H] Estradiol 17-
(β-d-Glucuronide) 
([3H]-E217βG) 
[3H]-
Daunorubicin 
[3H]-
Daunorubicin 
[3H]-Docetaxel 
 
[3’,5’,7’-
3H(n)]-
Methotrexate 
[3H]-Methotrexate 
[G-3H]-
Digoxin 
[6,7-3H] 
Estradiol 17-(β-
d-Glucuronide) 
([3H]-E217βG) 
[3H]-Etoposide 
  
[3H]-Mitoxantrone 
[3H]-
Paclitaxel 
[3H]-
Leukotriene C4 
([3H]-LTC4) 
[6,7-3H] 
Estradiol 17-
(β-d-
Glucuronide)  
([3H]-E217βG) 
  
[14C]-2-Amino-1-
Methyl-6-
Phenylimidazo[4,5-
b]Pyridine  ([14C]-
PhIP) 
[7-methoxy-
3H]-Prazosin 
 
[3’,5’,7’-
3H(n)]-
Methotrexate 
   
[3H]-
Vinblastine 
 
[3H]-Paclitaxel 
   
[G-3H]-
Vinblastine 
Sulfate 
 
[3H]-
Vinblastine 
   
 
 
 
